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ABSTRACT 
 
Background: Hypertensive disorders of pregnancy remain one of the major contributions to maternal 
and fetal morbidity and mortality around the globe. Pre-eclampsia is a hypertensive disorder of 
pregnancy which complicates 3-10% of pregnancies worldwide. It is a multi-organ disorder affecting 
the maternal system, thereby creating a major setback in terms of targeting the aetiology.  One of the 
main organs disrupted is the kidneys and a dysregulation of uric acid levels and the renin angiotensin 
system have been implicated in pre-eclampsia. Therefore, the aim of this study is to investigate the 
gene polymorphisms of uric acid, aminopeptidase-N, the angiotensin receptor IV, and plasma levels 
of the receptor in pre-eclampsia compared to normotensive pregnancies. 
Materials and Methods: This was a retrospective study consisting of 637 blood samples of which 
280 were normotensives and 357 pre-eclamptic. Pre-eclampsia was subdivided into early (n=187) 
and late onset pre-eclampsia (n=170). DNA was isolated from blood samples using the Thermo 
Scientific GeneJet whole blood Genomic DNA purification mini Kit. Single nucleotide 
polymorphisms of uric acid (rs505802, rs1014290, rs12129861, rs2231142), the angiotensin receptor 
IV (rs18059) and aminopeptidase-N (rs6496603) were amplified using the TaqMan genotyping assay. 
Plasma levels of angiotensin receptor IV were also measured using the ELISA in pre-eclampsia and 
compared to normotensives.   
Results: We found that rs505802 was higher in late onset pre-eclampsia compared to early onset pre-
eclampsia and the normotensive group. We also observed a significant elevation of rs1014290 in early 
onset pre-eclampsia compared to late onset pre-eclampsia and the normotensive group. Gene 
polymorphisms of the angiotensin IV receptor (rs18059) and aminopeptidase-N (rs6496603) showed 
no significant association with pre-eclampsia. However, plasma levels of angiotensin IV receptor 
were significantly lower in pre-eclampsia than in normotensives. Furthermore, we found that the 
levels decreased with the severity of pre-eclampsia. 
Conclusion: The single nucleotide polymorphisms of uric acid (rs505802, rs1014290) are associated 
with the pathogenesis of pre-eclampsia. Furthermore, plasma levels of angiotensin IV are decreased 
in pre-eclampsia, indicating a dysregulation of the renin angiotensin system in pre-eclampsia. 
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ABSTRACT-ISIZULU 
 
Amathuluzi asetshenzisiwe: Lolucwaningo lubizwa nge-retrospective lusebenzise amagazi awu 637 
aphuma kwabanomfutho osesimweni sempilo (normotensives) abangu 280 Kanye nabanomfutho 
ophakeme wegazi kubakhulelwe (pre-eclamptic) abangu 357. Abanomfutho ophakeme wegazi 
baphinde bahlukaniswa izigaba ezimbili, ezibizwa nge early (n=187) ne late onset (n=170). Ufuzo 
egazini lutholakale ngokusebenzisa I Thermo Scientific GeneJet whole blood Genomic DNA 
purification mini Kit. Ama Single nucleotide polymorphisms e uric acid (rs505802, rs1014290, 
rs12129861, rs2231142), angiotensin receptor IV (rs18059) nawe aminopeptidase-N (rs6496603) 
acubulungwe ngokusebenzisa i- TaqMan genotyping assay. Izinga le-angiotensin receptor IV egazini 
likalwe ngokusebenzisa i-ELISA kwabanomfutho wamandla ophakeme kwabakhulelwe (pre-
eclamptics) makuqhathaniswa nabanomfutho osesimweni sempilo (normotensive).   
 
Imiphumela: Sithole ukuthi amazinga e rs505802 abephezulu ku late onset pre-eclampsia 
makuqhataniswa ne early onset pre-eclampsia ne normotensive. Siphinde sabona ukukhuphuka 
kwenani le rs1014290 ku-early onset pre-eclampsia makuqhathaniswa ne late onset pre-eclampsia 
Kanye ne normotensive group. Ama gene polymorphisms we angiotensin IV receptor (rs18059) 
Kanye ne aminopeptidase-N (rs6496603) awakhombisanga mahluko ekuhlobaneni ne pre-eclampsia. 
Kodwa, inani le angiotensin IV receptor egazini abehlile kulabo abanomfutho wamadla ophakeme 
egazini (pre-eclampsia) makuqhathaniswa nalabo abanomfutho osesimweni sempilo (normotensive). 
Siphinde sathola ukuthi lokwehla kuhambisana nokubhebhetheka kwesifo somfutho wamadla 
ophakeme egazini. 
 
Ukuvala: I single nucleotide polymorphisms ye uric acid (rs505802, rs1014290) ihlobene nokuqala 
kwesifo somfutho wamadla ophakeme egazini kwabakhulelwe (pre-eclampsia). Futhi, izinga le 
angiotensin IV egazini lehlile kulabo abanomfutho wamadla ophakeme egazini kwabakhululwe (pre-
eclampsia), okukhombisa ukungalawuleki kwe renin angiotensin system kulabo abanomfutho 
wamadla ophakeme egazini (pre-eclampsia). 
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BACKGROUND AND LITERATURE REVIEW 
1.1 INTRODUCTION 
Hypertensive disorders of Pregnancy (HDP) are a major cause of maternal and neonatal morbidity 
and mortality worldwide (Brown et al., 2018). In South Africa, HDP are the commonest direct cause 
of maternal deaths and account for approximately 18% of all deaths (Saving Mothers’ Annual Report, 
2017). Most of these deaths are due to severe pre-eclampsia and eclampsia and are predominantly 
ascribed to intracranial hemorrhage. 
The International Society for the Study of Hypertension in Pregnancy classification of HDP has 
evolved through the years and is now categorized as follows: 
• chronic hypertension occurring prior to pregnancy or for the first time at less than 20 weeks 
of gestation;  
• white-coat hypertension, known as high blood pressure (> 140 systolic and or >90 diastolic 
mm Hg) that occurs at a workplace or a clinic but normal (130/85 mm Hg) at home;  
• masked hypertension, which is defined as complicated and difficult to diagnose but occurs 
occasionally and usually detected by a 24-hour ambulatory monitoring device and 
• gestational hypertension which is elevated blood pressure after 20 weeks of gestation without 
proteinuria.  
It is accepted that if gestational hypertension occurs after 34 weeks of gestation, it may progress to 
pre-eclampsia (Brown et al., 2018). 
 
1.2 PRE-ECLAMPSIA 
Pre-eclampsia (PE) is a disorder unique to human pregnancies and is defined as new onset 
hypertension that occurs after 20 weeks of gestation, characterized by an aberrant increase in blood 
pressure (systolic blood pressure level of ≥140mmHg and or a diastolic blood pressure level of 
≥90mmHg) and the presence of proteinuria  above 0.3g in a 24 hour  sample (Gathiram and Moodley, 
2016).  Pre-eclampsia  also affects systemic organs such as the lungs, brain (eclampsia), kidney and 
the liver (HELLP syndrome) (Gathiram and Moodley, 2016). In some cases hypertension may occur 
without proteinuria but include complications such as thrombocytopenia, acute kidney dysfunction 
and fetal restriction (Brown et al., 2018). Furthermore, it is a marker for  long term complications 
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such as cardiovascular diseases and diabetes for both the mother and the baby (Brown et al.,2018). 
Currently delivery of the baby is the only cure as PE resolves with delivery of the placenta. 
 
Pre-eclampsia is associated with hypo-perfusion of the placenta which results in placental ischemia 
and the release of placenta-derived factors into maternal circulation (Burton et al., 2019). These 
factors trigger a systemic inflammatory response and vascular endothelial damage. Placenta ischemia 
also triggers uric acid production (Mador et al.,2013). Hyperuricemia precedes proteinuria and 
hypertension, possibly indicating uric acid involvement in PE pathogenesis (Nahar et al.,2020). 
However, it  is unclear whether uric acid may be used as a marker for PE diagnosis (Zangana et 
al.,2018). Nonetheless,  a correlation between increased uric acid (hyperuricemia) and maternal and 
fetal morbidity implicating its diagnostic value in predicting PE development has been reported 
(Zangana et al.,2018). 
 
1.3 CLASSIFICATION OF PRE-ECLAMPSIA 
Pre-eclampsia is classified into superimposed pre-eclampsia, pre-eclampsia and eclampsia. 
 
1.3.1 Superimposed pre-eclampsia 
Superimposed pre-eclampsia commonly occurs in women with chronic hypertension, resulting in 
maternal and fetal complications (Magee et al., 2014). Abnormality of the kidneys may manifest in 
superimposed pre-eclampsia before 20 weeks of gestation and is characterized by increased blood 
pressure and proteinuria at 20th weeks of gestation (Watanabe et al., 2013). 
1.3.2  Pre-eclampsia 
Women with PE are at a risk of developing severe complications such as high levels of hypertension, 
renal diseases, cardiac diseases, and diabetes mellitus (Barrett et al., 2014). The pathogenesis of PE 
involves deficient trophoblast migration emanating from increased trophoblast cell apoptosis 
(Naicker et al., 2019). This defective trophoblast invasion leads to a lack of physiological conversion 
of spiral arteries within the myometrium (Labarrere et al,.2017). This leads to reduced utero-placental 
perfusion pressure (RUPP) and placental hypoxia (Natale et al,.2018). 
 
1.3.3 Sub-classification of pre-eclampsia 
Pre-eclampsia may be sub-categorized according to gestational age and severity. Based on the onset 
of PE, it may be classified into: 
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i) Early onset pre-eclampsia - ≤ 33 weeks 6 days of pregnancy. 
ii) Late onset pre-eclampsia- ≥ 34 weeks of pregnancy (Lisonkova and Joseph, 2013). 
 
Based on its severity, this complication of pregnancy may be classified into mild and severe PE  
i) Mild pre-eclampsia is characterized by a blood pressure > 140/90 < 160/110 mmHg, and 
proteinuria <300 mg but not more than 2.0 g in a 24-hour urine sample (++) on a dipstick) 
(Watanabe et al., 2013).  
ii) Severe pre-eclampsia is characterized by a blood pressure of greater than 160/110 mmHg 
and urinary protein concentration >2.0 g in a 24-hour urine sample (+++) on a dipstick) 
(Watanabe et al., 2013). 
 
1.3.4 Eclampsia 
This is a condition characterized by seizures associated with PE (Watanabe et al., 2013). Factors such 
as cerebral edema and cerebral vasospasm are accountable for this condition (Soggiu-Duta et 
al.,2019). Most cases  of eclampsia occur during the antepartum period but may also occur during the 
intrapartum  and postpartum periods (Mersha et al.,2019).  
 
1.4 PREVALENCE OF PRE-ECLAMPSIA  
Pre-eclampsia complicates 10% of pregnancies worldwide (Berhe et al., 2018). More than 500 000 
fetal and 70 000 neonatal deaths occur each year due to PE (Brown et al., 2018).  In Africa, 270 000 
maternal deaths occur every year with approximately 76 000 attributed to PE development (Vata et 
al., 2015). The incidence of PE and eclampsia is 5.8%, which is remarkably high considering the 
frequency is only recorded from Durban, South Africa and that the total frequency of HDP in South 
Africa is 12% (Moodley et al., 2016). 
 
 
1.5 RISK FACTORS OF PRE-ECLAMPSIA  
The pathogenesis of PE is associated with pre-existing factors that include renal diseases, chronic 
hypertension, type 2 diabetes, autoimmune disorders and thrombophilia syndromes (Brown et 
al.,2018).  Other factors that increase the risk of PE development include: metabolic syndrome, 
maternal age (Grieger et al., 2018), nulliparity (North et al., 2011), insulin resistance (Hauth et al., 
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2011), immune factors, nutrient deficiency (calcium, antioxidants, vitamins) and genetic disposition 
(Sánchez-Aranguren et al., 2014).  
 
1.6 PATHOGENESIS OF PRE-ECLAMPSIA 
Pre-eclampsia is a two-stage model condition (Figure 2). The first stage is associated with defective 
placentation and a lack of spiral artery remodeling that leads to a decrease in blood supply that meets 
the oxygen and nutrient needs of the developing fetus. This diminished oxygen supply, has a domino 
effect in that it causes placental hypoxia and ischemia, that lead to the second stage where, placental-
derived particles and/or factors are released into maternal circulation (Naljayan and Karumanchi, 
2013). These placental-derived particles contribute to the pathogenesis of PE as they have the capacity 
to initiate an exaggerated inflammatory response (Redman and Sargent, 2001), which leads to the 
widespread endothelial dysfunction that characterizes PE (Tannetta and Sargent, 2013).  
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Figure 2: Diagrammatic representation of the stages of pre-eclampsia:  
 
Adapted from (Borzychowski et al.,2006). Poor placentation leads to abnormal spiral artery remodeling which 
promotes the release of placental factors or particles. These factors initiate a systemic inflammatory response 
with subsequent dysfunction of maternal vascular endothelium that manifests as the clinical signs of PE. 
1Interuterine Growth Restriction; 2Soluble fms-like tyrosine kinase-1. 
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1.7 THE ROLE OF GENETICS IN THE PATHOPHYSIOLOGY OF PRE-
ECLAMPSIA 
An alteration of genes at distinct loci may contribute to the predisposition of PE development. 
Furthermore, one gene may not be liable for all PE cases but a number of genes may contribute to 
subdivisions of the disease (Cox et al.,2011). To support this statement, a study was conducted to 
determine the subcategories of PE based on plasma membrane protein expression and three groups 
were identified: angiogenesis, mitogen-activated protein kinase signaling, and hormone biosynthesis 
and metabolism (Cox et al., 2011). In addition, environmental factors may also contribute to the 
pathogenesis of PE, these include: physiological stress (Vianna et al., 2011)  and vitamin D deficiency 
(Naidoo et al., 2019) 
Maternal and fetal genetic functions have been reported to be in conflict during pregnancy. An 
increased maternal immune response to trophoblast invasion leads to reduced decidualization and 
placentation. Interestingly, fetal genes function to improve fetal development by increasing nutrient 
supply to the baby, whereas maternal genes oppose this to secure maternal health; this conflict 
between fetal and maternal genes exacerbate  complications of PE (Varas et al.,2018). In addition, 
fetal genes elevate maternal blood pressure in order to improve utero-placental blood flow but 
maternal genes resist this and may lead to endothelial dysfunction (Varas et al.,2018). The pathway 
affected in this regard is the vascular endothelial growth factor (VEGF) signaling pathway. This 
pathway is responsible for angiogenesis and the regulation of endothelial cell function (Ali et 
al.,2019; Echeverria et al.,2020; Kaczynski et al.,2020). 
 
The circulating and placental soluble form of VEGF receptor: fms related tyrosine kinase (sFlt-1) is 
elevated in PE, this decreases free circulating VEGF, thus inhibiting their role to activate angiogenesis 
endothelial integrity management (Echeverria et al.,2020). Inactive free VEGF in the kidneys 
promotes endotheliosis and proteinuria (Echeverria et al.,2020). Furthermore, poor trophoblast 
invasion and reduced uteroplacental blood flow lead to placental ischemia (Echeverria et al.,2020), 
hypoxia and an increase reactive oxygen species (ROS), which in turn, leads to increased oxidative 
stress (Sánchez-Aranguren et al., 2014). 
 
Pre-eclamptic patients have high levels of oxidative stress and low level of antioxidants. In low- and 
middle- income  countries, pregnant women with a deficiency of antioxidants and an increase in 
oxidative stress develop PE (Auoache et al.,2018; Rana et al.,2019). Antioxidants aid in precluding 
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the process of oxidation, which produces free radicals that can induce chain reactions resulting in cell 
destruction when activated ( Sánchez-Aranguren et al.,2014; Rana et al.,2019). Free radicals have 
also been proposed to initiate endothelial dysfunction (Chaudhary et al.,2020). Poor trophoblast 
invasion, hypoxia, placental ischemia, oxidative stress and inflammation trigger endothelial 
dysfunction. Endothelial dysfunction and maternal systemic inflammatory response manifest as the 
clinical signs of PE. The severity of endothelial dysfunction and inflammatory response presents as 
the different classes of PE. 
 
1.8 URIC ACID AND PRE-ECLAMPSIA  
Uric acid (UA) dysregulation has been indicated as one of the clinical signs of PE (Chen et al., 2016). 
Reports have shown a dramatic increase in uric acid levels in women with PE compared to normal 
pregnancies (Wu et al., 2012). Uric acid is found in purine derivative  foods such as fructose, fatty 
meat, seafood fruits, alcohol and is also synthesized naturally by the body through purine metabolism 
(El Din et al., 2017). This biological pathway is initiated by the activation of xanthine oxidase (XO). 
Xanthine Oxidase converts adenosine triphosphate into adenosine xanthine, then this is further 
converted into uric acid (Osungbade and Ige, 2011).  
 
1.8.1 Uric Acid Levels in Normal Pregnancies  
In the first and second trimester of pregnancy, UA levels drop by 20-25% lower than normal ranges 
of non-pregnant individuals (0.3-6.0 mg/dl) (Martin and Brown, 2010). This is due to an increase in 
glomerular filtration, an increase in uricosuric acid, and a decrease in proximal tubular reabsorption 
(Parrish et al., 2010).  In the third trimester, levels begin to rise gradually as a result of high fetal 
development and low uric acid clearance, thereby reaching levels equivalent to non-pregnant 
individuals (Sultana et al., 2013) (Figure 3). 
 
1.8.2 Uric Acid Levels in Pre-eclampsia 
Levels of uric acid in PE differ from those in normal pregnancies. In Pe, uric acid levels rise 
throughout pregnancy (Wolak et al.,2015; Nair and Savitha, 2017). Pre-eclampsia is displayed with 
renal dysfunction, oxidative stress and placental ischemia. All these manifestations contribute to the 
elevated levels of uric acid in PE. It is well documented that angiotensin II is a vasoconstrictor and 
therefore ascribes to reduced renal blood flow, low urate secretion and low glomerular filtration rate, 
which in turn lead to reduced uric acid clearance (Sultana et al., 2013; Wolak et al.,2015). Reduced 
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uric acid clearance results in hyperuricemia which activates sympathetic activity and subsequently 
hypertension, thus aggravating PE (Mumford et al., 2013;Khurshid et al., 2016). (Figure 3). 
 
 
 
Figure 3: Levels of Uric Acid in Normal pregnancies compared to Pre-eclampsia:  
 
Adapted from (Many et al,.1996). Uric acid (UA) is involved in the pathogenesis of pre-eclampsia. In early 
stages of normal pregnancy, UA levels drop due to an increase in glomerular filtration rate (GFR) and an 
increase in uricosuric action of estrogen. However, in mid pregnancy serum uric acid levels rise gradually to 
reach 240-300μmol/l at term-equivalent to levels in non-pregnant women. This may result from hypovolemia 
that causes an increase in uric acid reabsorption and a decrease in UA secretion. However, in PE UA levels rise 
throughout the pregnancy and result in placental hypoxia and ischemia in pre-eclampsia. 
 
Uric acid has been classified as a pathogenic factor in PE (Bainbridge and Roberts, 2008). An 
elevation in uric acid levels at 10 weeks of gestation has been noted in women who develop PE at a 
later stage in pregnancy (Bainbridge and Roberts, 2008). Uric acid potentiates PE by stimulating 
inflammation, oxidative stress, and endothelial dysfunction (Bainbridge and Roberts, 2008). In 
addition, Powers et al., (2006) suggested that hyperuricemia results in hypertension and proteinuria, 
which are clinical signs commonly used to diagnose PE (Powers et al., 2006). 
 
Uric acid not only promotes hypertension in PE, but also contributes to poor trophoblast invasion 
(Kang et al., 2004). During normal placentation, cytotrophoblast cells invade the spiral arteries for 
proper vascular remodeling, and this expands or vasodilates the smooth muscles of the vessel walls 
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for sufficient flow of blood to the developing fetus. However, in PE, there is poor trophoblast 
invasion, improper spiral artery remodeling and consequently vasoconstriction of smooth muscles. 
This leads to reduced blood supply, and hypoxia (Burton et al.,2019). In a hyperuricemic 
environment, nitric oxide (NO) is decreased in endothelial cells and this contributes to poor 
trophoblast invasion (Zhen et al.,2017). Nitric oxide is a potent vasodilator which aids in relaxation 
of endothelial cells and trophoblast cell migration into the spiral arteries. This evidence suggests the 
role of uric acid in the pathogenesis of PE, particularly in women who experience elevated circulating 
uric acid levels at 10 weeks of pregnancy (Bainbridge and Roberts, 2008). Therefore, hyperuricemia 
is reported to be an early predictor of PE. 
 
The use of UA as a predictor of PE is proposed differently by some studies (Bainbridge et al.,2008; 
Ryu et al.,2019). These studies suggest that PE occurs prior to hyperuricemia which occurs as a result 
of renal injury in PE (Kondareddy and Prathap, 2016). Moreover, it has been mentioned that placental 
ischemia activates purine metabolism, resulting in hyperuricemia in PE (Kang et al., 2004). Hypoxia 
is one of the resultant causes of poor placentation in PE. The relationship between hypoxia and uric 
acid has been established (Many et al., 1996). In a hypoxic environment, adenosine triphosphate 
(ATP), is broken down into adenosine monophosphate, which is further broken down to adenosine, 
hypoxanthine then into the end product, which is uric acid (López-Cruz et al., 2016) causing  
hyperuricemia in PE.  
 
1.8.3 Uric Acid Levels and Fetal Outcome 
Hyperuricemia has been implicated as a predictor of fetal outcome in PE. Studies have found that 
women with hyperuricemia occurring before 35 weeks of gestation have babies with adverse fetal 
outcome (Williams and Galerneau, 2002).  About 56% of women with hyperuricemia had intrauterine 
growth restriction (IUGR) and intrauterine death (IUD) (Priya et al., 2016). Hyperuricemia was also 
reported to have a negative impact on fetal birth weight (Sahijwani et al., 2012). Hussain et al., (2011) 
mentioned that 72% of babies born from mothers with hyperuricemia had low birth weights, while 
62% of babies from woman with normal uric acid levels had normal birth weights (Hussain et al., 
2011). Another study reported on fetal outcome from pregnancies complicated with both 
hyperuricemia and pre-eclampsia. About 23.3% of these pregnancies delivered small-for-gestational-
age (SGA) babies, while pre-eclamptic women without hyperuricemia only had 9.3% of SGA babies 
(Khaleeq, 2015). 
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1.9 GENE POLYMORPHISM OF URATE TRANSPORTING PROTEINS 
Hyperuricemia is also influenced by genetic determinants, as well as heritability (Nath et al., 2007; 
Sun et al., 2014). Target organ destruction in patients with hypertension are associated with genetic 
factors (Li et al., 2016a).  Therefore, genome-wide association studies have identified genes that 
regulate serum uric acid concentration. Gene polymorphisms of uric acid  such as SLC, ABCG2 were 
initially reported to be involved with chronic renal injury (Bhatnagar et al.,2016). Furthermore, gene 
polymorphisms in Chinese populations affect genetic variations on the regulation of serum uric acid 
levels in humans (Sun et al., 2014).  
 
Sun et al., (2014) studied the association between gene polymorphisms of 11 loci (PDZK1, GCKR, 
LRP2, SLC2A9, ABCG2, LRRC16A, SLC17A1, SLC17A3, SLC22A11, SLC22A12 and SF1) and 
serum uric acid concentrations in a male and female Chinese population. They reported that SLC2A9 
and GCKR variants regulate uric acid concentration in Chinese males while SF1 and SLC2A9 were 
associated with uric acid levels irrespective of sex. SLC22A12 polymorphism correlates with uric acid 
concentration in females (Sun et al., 2014a). However, due to the existence of variation in allelic 
frequencies and effect sizes across different ethnicities, replication studies are required to clarify this 
effect (Nath et al., 2007).  
 
 The SNPs in this study were randomly selected dependent on their association with hyperuricemia 
identified in gout (Sun et al.,2014). It should also be noted that hyperuricemia is a feature of pre-
eclampsia (Le et al.,2019). Therefore, the urate transporter gene polymorphisms [(Glucose 9 
transporter,SLC2A0LGLUT9): rs1014290, SCL22A12 (Urate 1 transporter, URAT1):rs505802, 
(Postsynaptic density protein, PDZK1,CD160): rs12129861, (ATP-binding cassette super-family G 
member 2, ABC G2: rs2231142)] will be evaluated in a homogenous group of Black African pregnant 
women of Zulu ethnicity. These genes play an important role in uric acid regulation in the kidneys. 
The kidneys are accountable for the daily excretion of 70% of uric acid (Maesaka and Fishbane, 1998; 
El Din et al., 2017; Nair and Savitha, 2017).Although uric acid levels may be elevated by diet and 
life style factors, the aim of this study was to investigate the genetic association of urate transporters 
genes. Due to the retrospective nature of this study, uric acid levels were not available. The 
medications used to manage high blood pressure in pregnancy have not been reported to affect the 
levels of uric acid in pregnancy (Brown et al., 2018). 
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1.10 THE RENIN ANGIOTENSIN SYSTEM AND ANGIOTENSIN RECEPTOR IV 
(AT4) IN PE 
The renin-angiotensin-aldosterone (RAAS) system comprises a peptide cascade that plays a role in 
blood pressure regulation (Konoshita et al., 2014). The key components of the RAAS system are 
renin, angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin I (ANG I), 
angiotensin II (ANG II), angiotensin receptor type I (AT1R) and angiotensin receptor type 2 (AT2R) 
(Yang et al., 2013).  Disruptions of the cascade may contribute to the pathogenesis of pre-eclampsia 
(Aung et al., 2017). In PE, the RAAS system is the chief enhancer of low trophoblast invasion and 
the impaired remodeling of spiral arteries (Yang et al., 2013).  
 
A disruption of the RAAS system in pre-eclampsia leads to major changes in the RAAS homeostasis 
including renal impairment, body capillary constriction and a dysregulation in salt and water balance 
(Yang et al., 2013). Primary components of the RAAS system have been detected in the placenta (Li 
et al., 1998), therefore, synthesis of certain components of the RAAS system occur within the 
uteroplacental unit (Shah, 2006).  
 
In a normal pregnancy, the RAAS system undergoes changes to compensate for the demanding fetus. 
Plasma volume and ANG II levels are elevated compared to non-pregnant individuals. The elevation 
in ANG II is caused by the decrease in the AT1 receptor activation during pregnancy. Furthermore, 
normal pregnancies are less reactive to ANG II, therefore, an increase in ANG II does not compromise 
the pregnancy (Pirani et al., 1973; Yang et al., 2013). However, pre-eclamptic women show decreased 
levels of ANG II and salt and water retention (Scaife et al.,2017). Figure 4 outlines the RAAS system. 
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Figure 4: Schematic diagram of the RAAS System:  
 
Adapted from (Atlas, 2007). The kidneys secrete renin in response to reduced NACL, ECF volume, and arterial 
blood pressure. Renin activates Angiotensinogen which is produced by the liver into ANG 1. ANG1 is 
converted into ANG 2 by the angiotensin converting enzyme (ACE) produced in the lungs. ANG 2 acts as a 
binding site for AT1R, which is responsible for vasoconstriction, oxidative stress, sodium retention and cellular 
growth. AT2R is involved in vasodilation, oxygen release, apoptosis and inflammation. Lastly, AT4R plays a 
role in modulation of endothelial function.  
 
The association of gene polymorphisms of AGT, renin, AT1R, and AT2R have been investigated in 
pre-eclampsia. In pre-eclampsia, the distribution of the T allele and TT genotype of AGT is 
significantly increased compared to normotensive pregnancies (Aung et al., 2017). Furthermore, the 
distribution of the genotypes of renin, AT1R, and AT2R are identical in both pre-eclamptic and 
normotensive groups, thus indicating that these genotypes are not involved in the pathogenesis of PE 
(Aung et al., 2017). Another study, performed by Ji et al., (2013) on 41 tag single nucleotide 
polymorphisms (tag SNPs) in RAAS in a Chinese Han population reported that AGT rs3789678 
rs2493132, ACE 4305, and AGTR1 rs275645 are associated with non- pregnant  hypertension (Ji et 
al., 2013).  
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The AT4 receptor is a component of the RAAS system discovered in the early 2000s by Albiston et 
al., (2001). It  is a binding site for angiotensin IV (Vanderheyden, 2009). Angiotensin IV is 
responsible for memory, cognition, and vasodilation (Borghi et al., 2015). Therefore, the AT4 
receptor is associated with the regulation of blood flow, memory and vasodilation (Borghi et al., 
2015).  
 
 
1.11 PROBLEM STATEMENT AND SIGNIFICANCE 
Pre-eclampsia (PE) is one of the major categories of the hypertensive disorders of pregnancy 
worldwide (Rana et al., 2019). Maternal and fetal health are compromised greatly by PE which leads 
to premature deliveries and sometimes death of the mother and the fetus (Khan et al., 2019). Pre-
eclampsia occurs most frequently in sub-Saharan countries compared to those in high-income 
countries. A global estimate from data of nearly 39 million pregnancies suggests an incidence of 4.6% 
(Abalos et al., 2013). However, there is great regional variations in incidence rates ranging from 0.4% 
in Vietnam to almost 12% in primigravidae of African ancestry in Kwa Zulu Natal province, South 
Africa (Abalos et al., 2013; Moodley et al., 2016). 
 
The commonest direct cause of maternal deaths in South Africa are the hypertensive disorders of 
pregnancy in particular PE accounting for 18% of all deaths  (Ngene and Moodley, 2019).  It has been 
suggested that the high rates of PE and its associated complications in sub-Saharan African countries 
is due to inaccessibility to maternity care (Burton et al., 2019).  It has also been speculated that the 
human immune deficiency virus (HIV) may contribute to the high prevalence since the treatment 
(HAART therapy) is reported to result in immune reconstitution and thus PE susceptibility (Phoswa 
et al., 2019). Furthermore, 50% of PE cases have been reported as genetic and include factors such 
as race, environment, and social life (Hanson, 2019). This may be the case in the African population; 
however, justification is required since PE itself is still an enigma. Intensive research has been 
conducted through the years to resolve this. As a result, several questions remain unanswered. 
 
Pre-eclampsia is very complex since it is a multisystemic disorder (Gathiram and Moodley, 2016). 
The pathophysiology involves renal injury, hypertension, endothelial dysfunction, inflammation, 
placental hypoxia and ischemia, but the pathogenesis is unclear (Phipps et al., 2019). There is a need 
for further investigations in relation to the pathogenesis of PE as well as the genetic aspects in low- 
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and middle-income countries. The genes associated with the pathogenesis require investigation in 
order to target the source of the disease and to formulate methods that would prevent its occurrence 
for healthier pregnancy outcomes.  
 
1.12 AIMS AND OBJECTIVES OF THE THESIS 
 
1.12.1 Aims  
To establish the concentration and the prevalence of genetic variants of urate transporter genes 
[(SLC2A0LGLUT9): rs1014290, SCL22A12 (URAT1): rs505802, PDZK1 (CD160): rs12129861] 
related proteins, aminopeptidase-N (ANPEP-rs6496603) angiotensin IV receptor (AT4) (LNPEP-
rs18059), a new component of the renin angiotensin system in pre-eclampsia compared to 
normotensive pregnant controls. 
 
1.12.2 Objectives 
1. To compare variant gene polymorphisms of the urate transporter related genes [rs1014290 
(SLC2AL; GLUT9): rs505802 (SCL22A12; URAT1): rs12129864 (PDZK1; CD160)] in pre-
eclampsia versus normotensive controls, to elucidate the role of uric acid in the pathogenesis 
of pre-eclampsia using the TaqMan genotyping analysis. 
2. To assess the plasma concentration of the receptor (sAT-4), in pre-eclampsia versus 
normotensive controls using an enzyme-linked immune sorbent assay (ELISA). 
3. To compare variant gene polymorphisms of LNPEP (AT4R) (rs18059) and ANPEP 
(rs6496603) with pre-eclampsia development by performing the TaqMan genotyping assay. 
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Review Article: The Role of Uric Acid in Pre-eclampsia: Is Uric Acid a Causative 
Factor or a Sign of Pre-eclampsia 
 
This is a review article discussing the role of uric acid in pre-eclampsia. It has been published in 
current hypertension reports: 
Khaliq, O.P., Konoshita, T., Moodley, J. and Naicker, T., 2018. The Role of Uric Acid in Pre-
eclampsia: Is Uric Acid a Causative Factor or a Sign of Pre-eclampsia? Current Hypertension 
Reports, 20(9):80. 
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Research Article: Gene Polymorphisms of Uric Acid are associated with Pre-
eclampsia in South Africans of African Ancestry 
 
This chapter consists of a research article examining the association of gene polymorphisms of uric 
acid in pre-eclamptic women of African ancestry. 
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Abstract 
Objectives: To investigate the association of uric acid gene polymorphisms and Pre-eclampsia.  
Methods: 637 women of African ancestry [280 controls, 357 pre-eclampsia (early-onset=187, late-
onset=170] retrospectively. The rs505802, rs1212986 and rs1014290 SNPs were genotyped from 
purified DNA using real-time PCR.  
Results: CT genotype (rs505802) was higher in pre-eclampsia [Adjusted p=0.028*: OR (95% CI) = 
1.73 (1.258 - 2.442) and late-onset pre-eclampsia [Adjusted p=0.027*: OR (95 % CI) =1.75 (1.165 - 
2.2628) than controls. CT genotype (rs1014290) was higher in early-onset pre-eclampsia [Adjusted 
p value=0.040*: OR (95% CI) = 1.60 (1.102 - 2.325)] than controls.  
Conclusion: The genotyped rs505802 and rs1014290 are significantly associated with pre-eclampsia 
 
Keywords Pre-eclampsia, Single nucleotide polymorphisms, Uric acid, Hyperuricemia 
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Introduction 
Pre-eclampsia (PE) is a common cause of maternal and fetal complications worldwide, accountable 
for > 500 000 fetal deaths and > 70 000 maternal deaths [1]. Pre-eclampsia has a global prevalence 
of 5-8% [2]. Despite extensive research, the exact etiology of PE remains obscure, with the only 
known cure being the early delivery of the fetus and placenta [3, 4]. The pathogenesis of PE is 
influenced by environmental and genetic factors [5]. To date, the etiology of PE is unclear but studies 
suggest that it involves deficient trophoblast invasion and inadequate spiral artery transformation with 
resultant ischemia, oxidative stress, and hyperuricemia [2, 5]. 
Uric acid is a result of purine metabolism arising from purine nutritional products such as seafood, 
fruit-derived fructose, alcohol and organ meat [6]. The biological synthesis of uric acid is activated 
by the xanthine oxidase (XO) enzyme. [6]. The production of uric acid in PE is exaggerated compared 
to that of normal pregnancy [7]. Increased uric acid levels may arise from renal impairment noted in 
PE, or in an ischemic placenta [8]. It is reported that placental ischemia promotes the activation of 
XO, further activating uric acid production [9]. 
Despite several studies highlighting the role of uric acid in the etiology of PE, the data remains 
controversial [10-13]. Nonetheless, the uric acid elevation is reported to occur as early as 10 weeks 
of gestation thereby increasing the risk of PE development [5]. On the other hand, PE may manifest 
clinical features prior to hyperuricemia and cause renal impairment with resultant elevation in serum 
uric acid levels [12].  
An association of gene polymorphisms with serum uric acid elevation has been previously 
demonstrated [14-16]. Single nucleotide polymorphisms SNPs of PDZK1, GCKR, LRP2, SLC2A9, 
ABCG2, LRRC16A, SLC17A1, SLC17A3, SLC22A11, SLC22A12 and SF1 were mapped for serum 
uric acid association in both males and females in a Chinese population. The results revealed that 
SLC2A9 rs11722228, SF1 rs606458, and GCKR rs780094 SNPs altered serum uric acid concentration 
in males, whilst SF1 rs606458 and SLC2A9 rs3775948 altered uric acid concentration across both 
sexes [15]. Moreover, the gene SLC2A9 (GLUT9) was found to be associated with hyperuricemia in 
both Caucasians and Asians [16]. Also, Zhang et al., [14] genotyped the SNP rs2231142 of the 
ABCG2 gene and found an association with hyperuricemia in an American population consisting of 
European Americans, African Americans, Mexican Americans and Indian Americans [14]. 
Analogous reports also link the urate transporter 1(URAT1) gene with hyperuricemia [17], this gene 
is an anion transporter that functions mainly to control uric acid reabsorption within renal proximal 
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tubules. Nonetheless, in a Korean population, SNPs viz., rs7929627, rs75786299, rs3825017 and 
rs121907892 of the URAT1 gene are strongly associated with increased serum uric acid levels in 
individuals with gout [18]. Thus, the latter studies highlight the role of polymorphisms of the uric 
acid polymorphisms in various disease types, albeit most strongly in gout [14-16, 18]. It is well known 
that the kidney is affected in PE compared to normal pregnancies with a consequential elevation of 
serum uric acid [19-22]. All previous studies on uric acid polymorphisms have investigated them in 
relation to gout, as far as we are aware, there are no studies investigated in pregnant populations. 
Therefore, the four SNPs selected in this study were randomly chosen based on their association with 
hyperuricemia detected in individuals with gout [16, 17, 23]. The aim of this study was to determine 
the association and the prevalence of genetic variants of uric acid [(SLC2ALGLUT9): rs1014290, 
SCL22A12 (URAT1):rs505802, PDZK1 (CD160): rs12129861: (ABCG2): rs2231142] in South 
African women of African ancestry with PE. 
Materials and Methods 
Study Population and Design 
Stored samples of pregnant women (n=637) recruited from an urban hospital in Durban, South Africa 
were used for the purposes of this study. Informed consent for the storage and future studies was 
obtained following institutional ethical approval (BCA 338/17). Study groups included healthy 
normotensive pregnant women and women with a diagnosis of PE. The PE group was sub-divided 
into early (occurring <33 weeks plus 6 days of gestation; EOPE) and late-onset PE (occurring >34 
weeks of gestation; LOPE). Pre-eclampsia was defined as new-onset hypertension (systolic blood 
pressure ≥140mmHg and or diastolic blood pressure of ≥ 90mmHg) with or without proteinuria 
(300mg in a 24-hour quantitative urine test or at least 1+ on a urinary dipstick test). All blood pressure 
and proteinuria measurements were recorded at the time of admission to hospital or recorded at the 
time of recruitment for the controls. 
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DNA Isolation 
DNA was isolated from 500 µl of whole blood using the Thermo Scientific GeneJet whole blood 
Genomic DNA Purification Mini Kit (Thermo Scientific). Samples were stored at -20°C for 
genotyping analysis.  
TaqMan Genotyping of Uric Acid Gene Polymorphisms 
Four SNP probes were amplified to detect specific polymorphisms from purified DNA samples using 
TaqMan genotyping master mix (Applied Biosystems), according to manufacturer’s protocol. 
Genotyping of SNPs was performed using the QuantStudio 7 real-time Flex PCR (Life Technologies, 
California, USA). TaqMan reagents to run the polymerase chain reaction included: TaqMan universal 
master mix (x2), No Amp Erase UNG (12.5 µl), 20 X working stock of SNP Genotyping Assay (1.25 
µl), DNase-free water (5.25 µl), and 50 ng/µl of DNA (1 µl), with a total volume of 20 µl per well. 
Following PCR amplification, allelic discrimination results were analyzed using the QuantStudio 7 
Flex v1.3 software. To confirm our results, the experiments were repeated in two independent 
laboratories with the same cohort (University of KwaZulu-Natal, University of Fukui). 
Sample Size 
The sample size was determined by an institutional biostatistician. The Cohens effect was used to 
calculate the sample size. To assess a two-fold difference in the specified genes between study groups 
with 80% power and the probability of 95% assuming 50% controls, 274 participants were required 
with 137 participants per subgroup. A total number of 600 participants was expected, of which 400 
would be PE and 200 controls. The PE group was subdivided into early (n=200) and late (n=200) 
onset PE.  
Statistical Analysis 
The Hardy-Weinberg equilibrium (HWE) test was used to check for conformance to observed 
frequencies of the genotypes [24]. Frequency and percentage were used to describe the presence of 
the genotypes. Subgroups were compared using the Chi-squared test or Fisher’s exact test as 
appropriate. The strength of association was reported as odds ratios (OR) and 95% confidence interval 
(CI) for categorical data and Wilcoxon rank sum tests for numeric data. A p-value <0.05 was 
considered statistically significant. For table demographics analysis, one-way ANOVA test was 
performed, with the Graph pad prism 5 software (Graph Pad Software, San Diego, CA, USA). Also, 
the Bonferroni correction test was conducted for multiple comparisons. 
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Results 
This study consisted of 637 participants. The two main groups included the PE group (n=357; 56%) 
and the control group (n=280;44%). The PE group was subdivided into early (EOPE: n=187; 29%) 
and late pre-eclampsia (LOPE: n=170; 27%). 
Genotyping 
The association of gene polymorphisms of uric acid (rs505802, rs1014290, rs12129861, rs2231142) 
in PE is tabulated below. An allelic (Table 2) and genotypic comparison of frequencies were 
calculated and four genetic models tested; i.e. the codominant (equal effect of two alleles from a gene 
pair), dominant (alleles with the same phenotype irrespective of whether the paired allele is identical 
or not) [25], recessive (creates a phenotype only when the paired alleles are identical) and 
overdominant model (heterozygote has a greater effect compared to the homozygote) [26]. These four 
genetic models were tested for associations with PE for each of the three variants examined. (Table 
3, 4 and 5). The SNP rs2231142 of the ABCG2 gene showed a very low frequency of < 1% in our 
study population and is therefore not included in the results on table 2 and below. 
Allelic association of rs505802 (URAT 1) in Pre-eclampsia 
Pre-eclampsia vs Controls 
The frequency of the C allele (529 cases and 438 controls) and T allele (185 cases and 126 controls) 
showed no significant association with PE (C vs T: Adjusted p=0.480). Similarly, the frequencies of 
CC (199 cases and 173 controls), CT (131 cases and 88 controls), and TT (27 cases and 19 controls) 
showed no significant association with PE compared to controls [ (CC vs CT + TT: Adjusted 
p=1.000); (TT vs CC+CT: Adjusted p=0.360);  (Table 2)]. 
Early-onset pre-eclampsia vs Controls 
Early-onset pre-eclampsia was compared to the control group. The frequency of the C allele (292 
cases and 438 controls) and the T allele (82 cases and 129 controls) showed no statistical significance 
(C vs T: Adjusted p=1.000). Likewise, the frequencies of CC (117 cases and 173 controls), CT (58 
cases and 88 controls), and TT (12 cases and 19 controls) showed no significant difference between 
EOPE and the control group [(CC vs CT +TT: Adjusted p=1.000); (TT vs CC+CT: Adjusted 
p=1.000); (Table 2)]. 
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Late-onset pre-eclampsia vs Controls 
The C allele (237 cases and 434 controls) and the T allele (103 cases and 126 controls) frequencies 
were higher in the controls compared to LOPE. There was a significant difference between LOPE 
and controls [C vs T:  Adjusted p=0.028*: OR (95%CI) =1.49 (1.104 - 2.030)]. With regards to the 
frequencies of CC (82 cases and 173 controls), CT (73 cases and 88 controls), and TT (15 cases and 
19 controls), a significant difference was noted between TT and CC + CT in LOPE compared to the 
controls [(TT vs CC +CT: Adjusted p=0.015*: OR (95%CI) =1.74 (1.180 - 2.551)]. However, there 
was no significant difference between (CC vs CT+ TT: Adjusted p=1.000); (Table 2). 
Early-onset pre-eclampsia vs Late-onset pre-eclampsia 
The allele frequencies of C (292 EOPE and 237 LOPE) and T (82 EOPE and 103 LOPE) were 
significantly different between EOPE and LOPE [C vs T: Adjusted p=0.032*: OR (95%CI) = 1.55 
(1.105 - 2.168)]. Also, the frequencies of CC (117 EOPE and 82 LOPE), CT (58 EOPE and 73 LOPE), 
and TT (12 EOPE and 15 LOPE) showed a significant difference between EOPE and LOPE (TT vs 
CC+CT: Adjusted p=0.019*: OR (95%CI) =1.79 (1.176 - 2.736)]. In contrast, CC vs CT +TT showed 
no significant difference between EOPE and LOPE (Adjusted p=1.000).  The C and the T alleles 
were higher in controls compared to the EOPE and LOPE groups; (Table 2). 
 Allelic Association of rs12129861(PDZK1-CD160) in Pre-eclampsia 
Pre-eclampsia vs Controls 
The allelic frequency of C (409 cases and 329 controls) and T (305 cases and 231 controls) of 
rs12129861(PDZK1-CD160) were lower in the controls compared to PE. However, no significant 
association was observed between PE and the controls (C vs T: Adjusted p=1.000). The frequencies 
of CC (122 cases and 101 controls), CT (165 cases and 127 controls) and TT (70 cases and 52 
controls) also showed no significant association with PE. [(CC vs CT+TT: Adjusted p=1.000); (TT 
vs CT + CC: Adjusted p=1.000); (Table 2)]. 
Early-onset pre-eclampsia vs Controls 
The frequency of the C allele (207 cases and 329 controls) and the T allele (167 cases and 231 
controls) of rs12129861 showed no significant association with EOPE compared to controls (C vs T: 
Adjusted p=0.900). The C and T allele frequencies were lower in EOPE than in controls. Equally, 
frequencies of CC (58 cases and 101 controls), CT (91 cases and 127 controls) and TT (52 cases and 
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38 controls) were not significantly different in EOPE compared to controls [(CC vs CT+TT: Adjusted 
p=1.000); (TT vs CC + CT: Adjusted p=0.780); (Table 2)]. 
 
Late-onset pre-eclampsia vs Controls 
The frequencies of the C allele (202 cases and 329 controls) and the T allele (138 cases and 231 
controls) showed no significant difference in LOPE compared to controls (C vs T: Adjusted p=1.000). 
The C and T alleles were lower in LOPE compared to controls. Similarly, the frequencies of CC (64 
cases and 101 controls), CT (74 cases and 127 controls) and TT (32 cases and 38 controls) showed 
no significant association with LOPE (CC vs CT+TT: Adjusted p=1.000), (TT vs CC+CT: Adjusted 
p=1.000); (Table 2). 
Early-onset pre-eclampsia vs Late-onset pre-eclampsia 
The allelic frequencies of C (207 EOPE and 202 LOPE) and T (167 EOPE and 138 LOPE) were not 
significantly different between EOPE and LOPE (C vs T: Adjusted p=0.810). No significant 
difference was noted with the frequencies of CC (58 EOPE and 64 LOPE), CT (91 EOPE and 74 
LOPE) and TT (52 EOPE and 32 LOPE) between EOPE and LOPE [(CC vs CT+TT: Adjusted 
p=1.000); (TT vs CC+CT:  Adjusted p=0.570); (Table 2)]. 
Allelic Association of rs1014290 (GLUT 9) with Pre-eclampsia 
Controls vs Pre-eclampsia 
The frequency of the C allele (209 cases and 144 controls) and the T allele (503 cases and 414 
controls) of rs1014290 showed no significant association with PE compared to controls (C vs T: 
Adjusted p=0.480). Equivalently, the CC (25 cases and 20 controls), CT (159 cases and 104 controls) 
and TT (172 cases and 155 controls) were not significantly different in PE compared to controls [(CC 
vs CT+TT:  Adjusted p=1.000); (TT vs CC+CT: Adjusted p=1.000); (Table 2)]. 
Early-onset pre-eclampsia vs Controls 
The allelic frequency of C (122 cases and 144 controls) and T (82 cases and 155 controls) of 
rs1014290 were lower in EOPE compared to the controls. [C vs T: Adjusted p=0.072]. 
Correspondingly, the frequencies of CC (17 cases and 20 controls), CT (88 cases and 104 controls) 
and TT (82 cases and 155 controls) were significantly different between EOPE and controls (CC vs 
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CT+TT: [Adjusted p=0.040*: OR (95%CI) =1.60 (1.102 - 2.325)]. No significant association was 
found between EOPE and the control group with TT vs CC+CT:  Adjusted p=1.000); (Table 2). 
Late-onset pre-eclampsia vs Controls 
The frequency of the C allele (87 cases and 144 controls) and the T allele (251 cases and 414 controls) 
of rs1014290 SNP showed no significant association with LOPE (C vs T:  Adjusted p=1.000). The C 
and T alleles were lower in LOPE compared to the control group. Similarly, the frequencies of CC (8 
cases and 20 controls), CT (71 cases and 104 controls) and TT (90 cases and 155 controls) showed 
no significant difference between LOPE and the controls [(CC vs CT+TT:  Adjusted p=1.000); (TT 
vs CC+CT:  Adjusted p=1.000 ); (Table 2)]. 
Early-onset pre-eclampsia vs Late-onset pre-eclampsia 
The frequency of the C allele (122 EOPE and 87 LOPE) and the T allele (82 EOPE and 251 LOPE) 
did not show any significant difference between the EOPE and the LOPE group [C vs T:  Adjusted 
p=0.132].In the same way, the frequencies of CC (17 EOPE and 8 LOPE), CT (88 cases and 71 
LOPE) were not significantly different between EOPE and LOPE  [CC+CT vs TT: Adjusted 
p=0.073]. No significant difference was noted with CC vs CT+TT:  Adjusted p=0.300); (Table 2). 
 
Genotype Association of URAT1 (rs505802) with Pre-eclampsia 
Pre-eclampsia vs Controls 
The genotype frequencies CC (173 controls and 199 cases), CT (88 controls and 131 cases) and TT 
(19 controls and 27 cases) of rs505802 showed no significant association with PE in the codominant 
genetic model [(CC vs TT: Adjusted p=1.000 CC vs CT: Adjusted p=1.000 CT vs TT: Adjusted 
p=1.000)]. The dominant model showed no significant difference between the control group and PE 
(CC vs CT+TT: Adjusted p=1.000). Similarly, the genotype frequencies in the recessive model were 
not statistically significant between the controls and PE (CC+CT vs TT: Adjusted p=0.498). 
However, the overdominant genetic model showed a significant difference between the controls and 
PE, [TT+CC vs CT: Adjusted p=0.004**: OR (95% CI) = 1.73 (1.258 - 2.442)] with the CT genotype 
having an association with PE; (Table 3). 
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Early-onset pre-eclampsia vs Controls 
The genotype frequencies of CC (117 cases and 173 controls), CT (58 cases and 88 controls) and TT 
(12 cases and 19 controls) of rs505802 showed no significant association with PE in the codominant 
model [(CC vs TT: Adjusted p=1.000 ); (CC vs CT:  Adjusted p=1.000); (CT vs TT: Adjusted 
p=1.000)]. The dominant genetic model showed no significant association with PE (CC vs CT+TT, 
Adjusted p=1.000). Similarly, the recessive genetic model (CC + CT vs TT:  Adjusted p=1.000) and 
the overdominant genetic model were not statistically significant (TT+CC vs CT: Adjusted p=1.000); 
(Table 3). 
Late-onset pre-eclampsia vs Controls 
The genotype frequencies were CC (82 cases and 173 controls), CT (73 cases and 88 controls) and 
TT (15 cases and 19 controls). The codominant model, CC vs CT, showed significant association 
with LOPE [CC vs CT: Adjusted p=0.027*: OR (95 % CI) =1.75 (1.165 - 2.628)]. There was no 
significant association noted with CC vs TT: Adjusted p=0.661) and CT vs TT: Adjusted p=1.000). 
The dominant genetic model showed a statistically significant association of rs505802 with LOPE 
[CC vs CT+TT: Adjusted p=0.020*: OR (95% CI) = 1.74 (1.180-2.551)]. The CT genotype showed a 
strong association of rs505802 (URAT1) with LOPE. No statistical significance was found with the 
recessive genetic model in LOPE compared to controls (CC+CT vs TT: Adjusted p=1.000). The 
overdominant model displayed no association with LOPE compared to controls [CC+TT vs CT: 
Adjusted p=0.054]; (Table 3). 
Early-onset pre-eclampsia vs Late-onset pre-eclampsia 
The genotype frequencies of CC (117 EOPE and 82 LOPE), CT (58 EOPE and 73 LOPE) and TT 
(12 EOPE and 15 LOPE) in the codominant genetic model showed no significant difference: (CC vs 
CT: Adjusted p=0.630) and (CT vs TT: Adjusted p=1.000). Nevertheless, a significant association 
was noted between EOPE and LOPE with; [CC vs CT: Adjusted p=0.039*: OR (95% CI) =1.79 
(1.150-2.804)]. Similarly, the dominant genetic model was significantly different between EOPE and 
LOPE [CC vs CT+TT: Adjusted p=0.026*: OR (95% CI) = 1.79 (1.176-2.736)]. The recessive model 
was not significantly different between EOPE and LOPE (CC+ CT vs TT: Adjusted p=1.000). No 
significant association with LOPE was noted with the overdominant genetic model; [CT+TT vs CC: 
Adjusted p=0.078]; (Table 3). 
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Genotype Association of PDZK1 CD160 (rs12129861) with Pre-eclampsia 
Pre-eclampsia vs Controls 
The genotypic frequencies of CC (122 cases and 101 controls), CT (165 cases and 127 controls) and TT 
(70 cases and 52 controls) in the codominant genetic model showed no significant association between the 
controls and PE, [(CC vs TT: Adjusted p=1.000); (CC vs CT: Adjusted p=1.000); (CT vs TT: Adjusted 
p=1.000)]. The dominant genetic model was not significantly different between PE and the control group 
(CC vs CT+TT: Adjusted p=1.000). No significant difference was found between PE and controls in the 
recessive genetic model (CC+CT vs TT: Adjusted p=1.000) and the overdominant genetic model (TT+CC 
vs CT: Adjusted p=1.000); (Table 4). 
Early onset pre-eclampsia vs Controls 
The frequencies of CC (58 cases and101 controls), CT (91 cases and 127 controls) and TT (70 cases and 
52 controls) in the codominant genetic model showed no significant difference: [(CC vs TT: Adjusted 
p=1.000); (CC vs CT: Adjusted p=1.000); (CT vs TT: Adjusted p=1.000)]. Similarly, no significant 
association found with the dominant genetic model (CC vs CT +TT: Adjusted p=1.000), the recessive 
genetic model (CC+CT vs TT: Adjusted p=1.000) and the overdominant genetic model (TT+ CC vs CT, 
Adjusted p=1.000); (Table 4). 
Late-onset pre-eclampsia vs Controls 
The genotype frequencies of CC (64 cases and 101 controls), CT (74 cases and 127 controls) and TT (32 
cases and 52 controls) in the codominant model were not significantly different between the controls and 
LOPE: [(CC vs TT: Adjusted p=1.000); (CC vs CT: Adjusted p=1.000) and (CT vs TT: Adjusted p=1.000)]. 
Similarly, the dominant genetic model (CC vs CT + TT: Adjusted p=1.000), the recessive genetic model 
(CC+CT vs TT: Adjusted p=1.000) and the overdominant genetic model were not significantly associated 
with LOPE (TT + CC vs CT: Adjusted p=1.000) ;(Table 4). 
Early-onset pre-eclampsia vs Late-onset pre-eclampsia 
The frequencies of CC (58 EOPE and 64 LOPE), CT (91 EOPE and 74 LOPE) and TT (38 EOPE and 32 
LOPE) of the codominant genetic model showed no statistical significance between EOPE and LOPE: [(CC 
vs TT: Adjusted p=1.000); (CC vs CT: Adjusted p=0.808); (CT vs TT:  Adjusted p=1.000)]. The dominant 
genetic model displayed no significant difference between EOPE and LOPE (CC vs CT+TT: Adjusted 
p=0.748). Likewise, the recessive genetic model (CC+CT vs TT: Adjusted p=1.000) and the overdominant 
genetic model were not significant association with EOPE and LOPE (TT+CC vs CT:  Adjusted p=1.000); 
(Table 4). 
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Genotype Association of SLC2ALGLUT9 (rs1014290) with Pre-eclampsia 
 
Pre-eclampsia vs Controls 
The frequencies of CC (25 cases and 20 controls), CT (159 cases and 105 controls) and TT (172 cases and 
155 controls) of the codominant genetic model showed no significant association with PE: [(CC vs TT: 
Adjusted p=1.000); (CC vs CT:  Adjusted p=1.000); (CT vs TT:  Adjusted p=0.224)]. The dominant genetic 
model was not statistically different between PE and the controls (CC vs CT+TT: Adjusted p=1.000). 
Likewise, the recessive genetic model (CC+CT vs TT: Adjusted p=0.280) and the overdominant genetic 
model indicated no significant difference between PE and the control group (TT+CC vs CT: Adjusted 
p=0.243); (Table 5). 
Early onset pre-eclampsia vs Controls 
The frequencies of CC (17 cases and 20 controls), CT (88 cases and 104 controls) and TT (82 cases and 
155 controls) in the codominant model were not significantly associated with EOPE [CT vs TT: Adjusted 
p=0.072). No significant association was noted with: CC vs TT: Adjusted p=0.726) and CC vs CT: Adjusted 
p=1.000). The dominant genetic model demonstrated no significant association with EOPE (CC vs CT 
+TT: Adjusted p=1.000). Likewise, the recessive genetic model [CC+CT vs TT:  Adjusted p=0.053]and 
the overdominant genetic model (TT+CC vs CT) showed no association of rs1014290 with EOPE [TT+ CC 
vs CT: Adjusted p=0.142] ;(Table 5). 
Late-onset pre-eclampsia vs Controls 
The genotype frequencies of CC (8 cases and 20 controls), CT (71 cases and 104 controls) and TT (90 cases 
and 155 controls) in the codominant genetic model were not significantly associated with LOPE: [(CC vs 
TT: Adjusted p=1.000); (CC vs CT: Adjusted p=0.906) and (CT vs TT: Adjusted p=1.000)]. The dominant 
model showed no significant difference between LOPE and the controls (CC vs CT+TT: Adjusted 
p=1.000). Similarly, the recessive model :(CC+CT vs TT: Adjusted p=1.000) and the overdominant model 
was not significantly associated with LOPE (TT + CC vs CT: Adjusted p=1.000); (Table 5). 
Early-onset pre-eclampsia vs Late-onset pre-eclampsia 
The frequencies of CC (17 EOPE and 8 LOPE), CT (88 EOPE and 71 LOPE) and TT (82 EOPE and 90 
LOPE) of rs1014290 showed no significant association with EOPE and LOPE in the codominant genetic 
model: [(CC vs TT: Adjusted p=0.230); (CC vs CT: Adjusted p=0.938) and (CT vs TT: Adjusted p=0.652)]. 
The dominant model showed no significant association of rs1014290 with EOPE and LOPE (CC vs CT+TT: 
Adjusted p=0.432). In the same way, the recessive genetic model (CC+CT vs TT:  Adjusted p=0.305) and 
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the overdominant genetic model were not significantly associated with EOPE and LOPE (TT+CC vs CT: 
Adjusted p=1.000); (Table 5). 
 
 
Discussion     
The key findings in this study revealed that of the four SNPs selected, rs2231142 (ABCG2) has a 
frequency of <1% in our population and rs12129861 (PDZK1 CD160) showed no significant 
association with PE. However, rs505802 (URAT 1) and rs1014290 (GLUT 9) denote a significant 
association with PE. 
URAT 1 SLC22A12 (rs505802) 
The study demonstrates a strong association of the human urate transporter 1 (URAT 1 SCL22A12; 
rs502802) genetic variant with PE, specifically LOPE compared to the control group [Adjusted 
p=0.028*: OR (95% CI) = 1.73 (1.258 - 2.442)] (Table 3). Late-onset pre-eclampsia occurs after 34 
weeks of gestation and affects 75-80% of all pregnancy cases [27]. This condition is mainly associated 
with maternal health disorders which include metabolic syndrome, obesity, dyslipidemia, and insulin 
resistance [28]. Our findings are the first to demonstrate uric acid polymorphisms in pregnancy, 
however, they are similar to a previous study that reported URAT 1 gene association with increased 
inflammatory response in non-pregnant patients with metabolic syndrome, obesity, and hypertension 
[29].  
Notably, the human urate transporter gene (URAT 1) is responsible for uric acid reabsorption in the 
proximal tubule of the nephron [30]. A study investigating whether URAT 1 was a candidate gene for 
hyperuricemia or hypouricemia in a non-pregnant Korean population demonstrated a strong 
significance with hyperuricemia [OR=32.07, p=1.20×10−8] [18]. Although the current study has no 
clinical data on serum uric acid levels, we speculate that rs505802 may be involved with 
hyperuricemia found in PE, as well as the clinical manifestations are seen in the participants with 
LOPE. Moreover, the impairment of renal function may also lead to the disruption of uric acid 
regulation with resultant hyperuricemia[30]. Previous studies in a Chinese cohort with cardiovascular 
diseases have demonstrated that hyperuricemia is associated with elevated blood pressure, diabetes, 
obesity, and insulin resistance[31]. These symptoms are also risk factors for PE development [32]. 
Sultana et al., [33] also reported that increased serum uric acid levels stimulate inflammation, 
oxidative stress and endothelial dysfunction: all of which are characteristics of PE [33]. In addition, 
it was reported that the URAT 1 gene is found in adipocytes where it activates oxidative stress and 
inflammation in response to hyperuricemia [34]. Moreover, it has been mentioned that uric acid 
mediates inflammation and can, therefore, promote the production of pro-inflammatory cytokines 
such as IL-1β, IL-6, and the TNF-α through monocytes [35]. Increased concentration levels of TNF-
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α has been noted in PE individuals with a significant correlation with increased serum uric acid levels 
[35]. In addition, a previous study by Redman et al., [36] reported that pro-inflammatory cytokines 
are exaggerated in PE compared to healthy controls [36]. 
Noteworthy, in our study, pre-eclamptic individuals had a higher heterozygote genotype (CT) 
associated with PE; a heterozygous disadvantage since the heterozygous genotype (CT) increases the 
risk of PE during pregnancy. The CT genotype was more prevalent in PE (37%) [TT+CC vs CT: 
Adjusted p=0.004**: OR (95% CI) = 1.73 (1.258 - 2.442)] and in LOPE (42%) [CC vs CT: Adjusted 
p=0.027*: OR (95 % CI) =1.75 (1.165 - 2.2628)]  than the control group (31%) and EOPE (31%); 
(Table 3). Because it is very rare to find the association of a disease with a heterozygous genotype, 
these findings are similar to a study by Liu et al., [26] that found a heterozygous genotype to be 
protective against Tuberculosis [26]. Currently, there is no literature on heterozygous genotypes 
associated with pregnancy complications. However, in our case, individuals with the CT genotype 
may have a predisposition to PE development.  
 
PDZK1 CD160 (rs12129861) 
PDZK1 CD160 is a scaffolding protein, necessary for uric acid transporter activity [37]. In our study, 
there was no significant association of rs12129861 with PE (Table 4). Therefore, our results 
demonstrate that rs1212986 is not associated with the pathogenesis of pre-eclampsia or hyperuricemia 
in our study population. However, several studies have been conducted on Asian and European 
descent and these studies have reported the involvement of the PDZK1 CD160 gene, specifically the 
rs12129861 SNP, with a uric acid level in gout [15, 31, 37-39].  
 
SLC2ALGLUT9 (rs1014290) 
The GLUT 9 gene functions as a transporter for fructose, glucose and uric acid. It is located within 
kidney and liver cells [23]. In the present study, significant association was noted with rs1014290 in 
controls compared to EOPE [Adjusted p value=0.040*: OR (95% CI) = 1.60(1.102 - 2.325)] (Table 
2). The CT genotype was more prevalent within the EOPE group (47%) compared to controls (37%), 
confirming that individuals with the CT genotype are at a 1.6 risk fold of PE development (Table 2). 
Our study indicates that this gene is associated with the pathogenesis of EOPE. Early-onset pre-
eclampsia contributes to 5-20% of all cases of PE and is probably the greatest contributor to maternal 
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and fetal morbidity and mortality associated with this condition [27]. Early-onset pre-eclampsia has 
been reported to be more detrimental to the fetus than it is for the mother as it involves poor 
placentation that leads to intrauterine growth restriction and subsequently neonatal death [27]. More 
importantly, a study by Kristensen et al.,[40]  confirmed that kidney glomerular and proteinuria 
diseases are associated with EOPE. Hyperuricemia is a result of renal insufficiency since a decrease 
in the glomerular filtration causes an increase in tubular reabsorption and a decrease in uric acid 
secretion [41]. In contrast, GLUT 9 mutations result in hypouricemia, indicating an increase in urate 
excretion [42]. However, it has been mentioned that uric acid triggers endothelial dysfunction, 
advances hypertension, vascular and renal diseases [33]. An increase in maternal vascular resistance 
has been suggested to account for poor placentation in EOPE [27]. Similarly, a study published 
approximately 53 years ago showed that hyperuricemia was associated with hypertension [43]. 
Nonetheless, the GLUT 9 gene has been reported to directly lower blood pressure level in an Amish 
population, implicating that a mutation in this gene triggers high blood pressure [44].  
The current study has shown a strong association of the GLUT 9 gene with EOPE. These results are 
similar to that of a previous study that reports an inactivation of the gene coding for GLUT 9 in the 
liver of mice promoting severe hyperuricemia [45]. The latter findings suggest that damage to hepatic 
cells may lead to an inactivation of GLUT 9 and result in hyperuricemia. Interestingly, EOPE has 
been shown to have an aggressive hematological, arterial, renal, hepatic adverse maternal and fetal 
outcome in comparison to LOPE [27].  
Several studies have reported the association of GLUT 9 with uric acid [44-51]. Interestingly, Wang 
et al., [52], reported that hyperuricemia was strongly associated with hypertension in both males 
((SUA)> 420 μmol/l ) and females ((SUA)> 360 μmol/), thus pregnant individuals with 
hyperuricemia may be susceptible to PE development [52]. Vitart et al., (2008) also showed that the 
C>T alleles of this SNP were associated with hyperuricemia in patients with gout from the northern 
and western Europe [53]. Moreover, these alleles are also associated with hyperuricemia in a 
Minnesota Chinese ethnic Hmong population [39]. Nonetheless, our findings may provide an 
explanation as to why women of African ancestry seem to have the more clinically aggressive form 
of PE, which is EOPE and have high prevalence rates of renal impairment and end-stage renal 
disorder [54]. Early-onset PE is more aggressive since it occurs due to poor placentation, which could 
cause intrauterine growth restriction followed by death of the fetus [27]. 
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ABCG2 (rs2231142) 
We found a frequency of < 1% in our study population and this is in keeping with  a  study by Zhang 
et al., [14] which showed a significant association of rs2231142 with hyperuricemia in four American 
population groups [European Americans (p = 2.37 × 10−67), Mexican Americans (p = 6.97 × 10−9), 
African Americans (p = 3.98 × 10−5), and Indigenous Americans (p = 5.33 × 10−4) with gout. 
However, significance was strongly noted in males and menopausal women compared to women in 
their reproductive phase of life. No data was reported on pregnant women; nevertheless, it was 
concluded that rs2231142 may be regulated by sex hormones [14].  
                                                                                                                                                                                                                                                                                                                                                                                                                                               
Strengths and Limitations of the Study  
To the best of our knowledge, this is the first study to examine uric acid polymorphisms in a South 
African population of African ancestry. In South Africa, PE has the highest prevalence in the province 
of KwaZulu-Natal (12%), occurring predominantly in primigravidae. The SNPs examined in this 
study do not represent all the SNPs available in uric acid, however, the four SNPs were selected based 
on their association with hyperuricemia in gout. Furthermore, this study utilizes retrospectively 
collected samples and therefore the number of samples was limited, and the levels of uric acid in pre-
eclamptic individuals were not available. 
Summary 
In this study, we hypothesized that gene variants of uric acid (rs505802-URAT 1, rs12129681-
PDZK1, rs1014290-GLUT 9) associated with hyperuricemia in gout are also associated with pre-
eclampsia. We demonstrate a prevalence of these variants within the study population and showed a 
strong association with PE. Therefore, this study provides new evidence linking these genetics 
variations associated with hyperuricemia in gout to PE. Furthermore, this study suggests that women 
of African ancestry are a risk factor for PE, particularly the EOPE subtype since this type of PE is 
known to be clinically associated with renal insufficiency. 
 
 
 
34 
 
Conclusion and Future Recommendations 
Two (URAT 1, rs505802; GLUT 9, rs1014290) of the three gene polymorphisms of uric acid 
showed significant association with PE. Therefore, these gene variants are involved in the 
pathogenesis of PE. However, further studies need to be conducted in an independent cohort 
with a larger sample size to confirm these results. In addition, the SNPs investigated in the 
current study may also be used to genetically screen patients for the risk of pre-eclampsia. 
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Appendices 
TABLE 1: Patient Demographics and Clinical Data 
 Control (n=280)  EOPE (n=187) LOPE (n=170) p-value 
Mean & SD     
Maternal Age (years) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
26.78±6.5 29.76±6.5   27.29±6.8  
<0.0001*** 
0.9701ns 
<0.0001*** 
Systolic BP (mmHg) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
109.8±12.3 158.9±13.7 151.4±12.1  
<0.0001*** 
<0.0001*** 
0.0026** 
Diastolic BP 
(mmHg) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
 67.65±8.4 102.0±9.3 98.23±6.6  
 
<0.0001*** 
<0.0001*** 
0.0300* 
Gestational Age 
(weeks) 
Control vs EOPE 
Controls vs LOPE 
EOPE vs LOPE 
38.24±1.7 28.51±4.2 37.06±1.9  
 
<0.0001*** 
<0.0001*** 
<0.0001*** 
Maternal Weight 
(Kg) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
72.79±16.8 81.96±18.5 73.48±18.2  
 
0.0120* 
0.2253ns 
0.3585ns 
Proteinuria 
Control vs EOPE 
Control vs LOPE 
LOPE vs EOPE 
0.00±0.06 1.51±0.74 1.44±0.69  
<0.0001*** 
<0.0001*** 
0.4970ns 
 
A p-value of <0.05 was considered statistically significant, *** = highly significant with a p-value of p<0.001. 
ns= not significant. SD (Standard deviation), EOPE (Early onset pre-eclampsia), LOPE (late onset pre-
eclampsia). 
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Table 2: Allelic Association of Rs505802, Rs12129861, Rs1014290 in Pre-eclampsia and Control 
groups 
ALLELES Rs505802 
OR (95%CI) 
p-value 
Rs12129861 
OR (95%CI) 
p-value 
Rs1014290 
OR (95%CI) 
p-value 
CONTROL vs PE    
FREQUENCIES 
CC, CT, TT 
Controls-(173;27%), 
(88;14%), (19;3%). 
1PE-(199;31%), 
(131;21%), (27;4.2%) 
2EOPE- (117;18%), 
(58;9%), (12;1.8%). 
3LOPE-(82;13%), 
(73;11%), (15;2.4%) 
Controls-(101;16%), 
(127;20%), (52;8%). 
PE-(122;19%), (165;26%), 
(70;11%). 
EOPE- (58;9%), (91;14%), 
(38;6%). 
LOPE-(64;10%), (74;12%), 
(32;5%) 
Controls-(20;3%), 
(104;16%), (155;24%). 
PE-(25;4%), (156;25%), 
(172;27%). 
EOPE-(17;3%), (88;14%), 
(82;13%). 
LOPE-(8;1%), (71;11%), 
(90;14) 
C vs T 
OR (95%CI) 
P VALUE 
1.20 (0.9292 -1.562) 
 
 Adjusted p value= 0.480 
(False) 
1.06 (0.8487 - 1.329) 
 
 Adjusted p value= 1.000 
(False) 
1.19 (0.9313 - 1.532) 
 
 Adjusted p value=0.480 
(False) 
CC vs CT/TT 
OR (95%CI) 
P VALUE 
1.12 (0.6112 - 2.067) 
 
 Adjusted p value= 1.000 
(False) 
1.07 (0.7177 - 1.594) 
 
 Adjusted p value=1.000 
(False) 
0.97(0.5313 - 1.800) 
 
Adjusted p value 
=1.000 (False) 
CC/CT vs TT 
OR (95%CI) 
P VALUE 
1.28 (0.9331 - 1.766) 
 
 Adjusted p value=0.360 
(False) 
1.09 (0.7832 - 1.508) 
 
 Adjusted p value=1.000 
(False) 
1.07 (0.7888 - 1.451) 
 
Adjusted p value 
=1.000 (False) 
CONTROL vs EOPE    
C vs T 
OR (95%CI) 
P VALUE 
1.03 (0.7543 - 1.417) 
 
 Adjusted p value= 1.000 
(False) 
1.15 (0.8821 - 1.497) 
 
 Adjusted p value= 0.900 
(False) 
1.39 (1.044 - 1.856) 
 
 Adjusted p value= 0.072 
(False) 
CC vs CT/TT 
OR (95%CI) 
P VALUE 
0.94 (0.4459 - 1.990) 
 
Adjusted p value=1.000 
(False) 
1.12 (0.7013 - 1.783) 
 
 Adjusted p value=1.000 
(False) 
1.29 (0.6593 - 2.544) 
 
Adjusted p value 
=1.000 (False) 
CC/CT vs TT 
OR (95%CI) 
P VALUE 
0.96 (0.6602 - 1.417) 
 
Adjusted p value=1.000 
(False) 
1.26 (0.8459 - 1.862) 
 
 Adjusted p value=0.780 
(False) 
1.60(1.102 - 2.325) 
 
 Adjusted p value 
=0.040* (True) 
CONTROL vs LOPE     
C vs T 
OR (95%CI) 
P VALUE 
1.49 (1.104 - 2.030) 
 
 Adjusted p value=0.028* 
(True)  
1.03 (0.7813 - 1.352) 
 
 Adjusted p value= 
1.000 (False) 
1.00 (0.7368 - 1.367) 
 
 Adjusted p value 
=1.000 (False) 
CC vs CT/TT 1.33 (0.6564 - 2.692) 1.02 (0.6237 - 1.657) 1.55 (0.6686 -3.612) 
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OR (95%CI) 
P VALUE 
 
 Adjusted p value=1.000 
(False) 
 
 Adjusted p value=1.000 
(False) 
 
 
 Adjusted p value 
=1.000 (False) 
CC/CT vs TT 
OR (95%CI) 
P VALUE 
1.74 (1.180 - 2.551) 
 
 Adjusted p value=0.015* 
(True) 
1.07 (0.7210 to 1.588) 
 
Adjusted p value 
=1.000 (False) 
 
1.10 (0.7477 - 1.610) 
 
Adjusted p value 
=1.000 (False) 
EOPE vs LOPE    
C vs T 
OR (95%CI) 
P VALUE 
1.55 (1.105 - 2.168) 
 
 Adjusted p value=0.032* 
(True) 
1.18 (0.8771 - 1.590) 
 
 Adjusted p value=0.810 
(False) 
1.40 (1.008 - 1.935) 
 
 Adjusted p value 
=0.132 (False) 
CC vs CT/TT 
OR (95%CI) 
P VALUE 
1.41 (0.6408 - 3.108) 
 
 Adjusted p value=1.000 
(False) 
1.10 (0.6511 - 1.858) 
 
 Adjusted p value 
=1.000 (False) 
2.01 (0.8450 - 4.793) 
 
Adjusted p value 
=0.300 (False) 
CC/TT vs TT 
OR (95%CI) 
P VALUE 
1.79 (1.176 - 2.736) 
 
Adjusted p value=0.019* 
(True) 
1.34 (0.8661 - 2.082) 
 
Adjusted p value 
=0.570 (False) 
1.55 (1.058 - 2.281) 
 
 Adjusted p value 
=0.073 (False) 
1Pre-eclampsia,2Early onset Pre-eclampsia,3Late onset Pre-eclampsia. A p-value of <0.05 was considered statistically 
significant. *= denotes significance, ** = p<0.01 and *** = p<0.001. Bonferroni corrected test was used for multiple 
comparisons. 
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Table 3: Genetic Association of Rs505802 (URAT 1) in Controls vs Pre-Eclampsia (PE) groups 
*= denotes significance of p<0.05, **=p<0.01 and *** = p<0.001. The Bonferroni test was used for multiple comparisons 
SNP GENETIC 
MODEL 
GENOTYPES CONTROL CONTROLS vs PE CONTROLS vs EOPE CONTROLS vs LOPE EOPE vs LOPE 
PE OR 
(95%CI) 
P- 
VALUE 
and 
Adjusted 
value 
EOPE OR 
(95% CI) 
P 
VALUE 
and 
Adjusted 
value 
LOPE OR 
(95%CI) 
P 
VALUE 
OR 
(95%CI) 
P  
VALUE 
and 
Adjusted 
value 
Rs505802 Codominant CC  
CC vs TT 
173 (27%) 199 
(31%) 
1.00 
1.24 (0.6636 - 
2.300) 
- 
1.000 
(False) 
 
117 
(18%) 
1.00 
1.07 
(0.5008 - 
2.290) 
- 
1.000 
(False) 
82 
(13%) 
1.00 
1.67(0.8056 
- 3.444) 
- 
0.661 
(False) 
1.00 
1.78(0.7934 
- 4.010) 
- 
0.630 
(False) 
CT 
CC vs CT 
88 (14%) 131 
(21%) 
1.00 
1.29 (0.9226 - 
1.815) 
- 
0.540 
(False) 
58 (9%) 1.00 
1.03 
(0.6836 - 
1.540) 
- 
1.000 
(False) 
73 
(11%) 
1.00 
1.75 (1.165 
- 2.628) 
- 
 0.027* 
(True) 
1.00 
1.79 (1.150 
- 2.804) 
- 
0.039 
(True) 
TT 
CT vs TT 
19 (3%) 27 
(4.2%) 
1.00 
1.05 (0.5489 - 
1.999) 
- 
1.000 
(False) 
12 
(1.8%) 
1.00 
1.04 
(0.4711 - 
2.312) 
- 
1.000 
(False) 
15 
(2.4%) 
1.00 
1.05(0.4989 
- 2.213) 
- 
1.000 
(False) 
1.00 
1.01(0.4373 
- 2.318) 
- 
1.000 
(False) 
Dominant CC 173 (27%) 199 
(31%) 
1.00 - 117 
(18%) 
1.00 - 82 
(13%) 
1.00 - 1.00 - 
CT + TT 107 (17%) 158 
(25%) 
1.12 (0.6112 - 
2.067) 
 
1.000 
(False) 
70 
(11%) 
1.03 
(0.7056 - 
1.515) 
 
1.000 
(False) 
88 
(14%) 
1.74 (1.180 
- 2.551) 
 
0.020* 
(True) 
1.79 (1.176 
- 2.736 
 
0.026* 
(True) 
 Recessive CC + CT 261 (41%) 330 
(52%) 
1.28 (0.9331 - 
1.766) 
 
0.498 
(False) 
175 
(27%) 
1.06 
(0.5026 - 
2.243) 
 
1.000 
(False) 
155 
(24%) 
1.33 
(0.6564 - 
2.692) 
 
1.000 
(False) 
 
1.41 
(0.6408 to 
3.108) 
 
1.000 
(False) 
  TT 19 (3%) 27 
(4.2%) 
1.00 - 12 
(1.8%) 
1.00 - 15 
(2.4%) 
1.00 - 1.00 - 
 Overdominant TT + CC 192 (30%) 226 
(35%) 
1.75 (1.258 - 
2.442) 
 
0.004** 
(True)  
129 
(20%) 
1.02 
(0.6835 to 
1.520) 
 
1.000 
(False) 
97 
(15%) 
1.64 (1.106 
- 2.437) 
 
0.054 
(False) 
1.67(1.085 - 
2.583) 
 
0.078 
(False) 
  CT 88 (14%) 131 
(21%) 
1.00 - 58 (9%) 1.00 - 73 
(11%) 
1.00 - 1.00 - 
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Table 4: Genetic Association of Rs12129861 (PDZK1 CD160) in Controls vs Pre-eclampsia (PE) groups 
 
*= denotes significance of p<0.05, **=p<0.01 and *** = p<0.001. The Bonferroni test was used for multiple comparisons 
SNP GENETIC 
MODEL 
GENOTYPES CONTROL CONTROLS vs PE CONTROLS vs EOPE CONTROLS vs LOPE EOPE vs LOPE 
PE OR 
(95%CI) 
P- 
VALUE 
and 
Adjusted 
value 
EOPE OR 
(95% CI) 
P 
VALUE 
and 
Adjusted 
value 
LOPE OR 
(95%CI) 
P VALUE 
and 
Adjusted 
value 
OR 
(95%CI) 
P  
VALUE 
and 
Adjusted 
value 
Rs12129861  Codominant CC  
CC vs TT 
101 (16%) 122 
(19%) 
1.00 
1.11 
(0.7139 - 
1.740) 
- 
1.000 
(False) 
58 
(9%) 
1.00 
1.27 (0.7501 - 
2.159) 
- 
1.000 
(False) 
64 
(10%) 
1.00 
1.03(0.5998 
- 1.768) 
- 
1.000 
(False) 
1.00 
1.31(0.72
67 - 
2.363) 
- 
1.000 
(False) 
CT 
CC vs CT 
127 (20%) 165 
(26%) 
1.00 
1.08 
(0.7573 - 
1.528) 
- 
1.000 
(False) 
91 
(14%) 
1.00 
1.25 (0.8194 - 
1.900) 
- 
1.000 
(False) 
74 
(12%) 
1.00 
1.08(0.7112 
- 1.663) 
- 
1.000 
(False) 
1.00 
1.36(0.84
85 - 
2.170) 
- 
0.808 
(False) 
TT 
CT vs TT 
52 (8%) 70 (11%) 1.00 
1.04 
(0.6760 - 
1.588) 
- 
1.000 
(False) 
38 
(6%) 
1.00 
1.02 (0.6201 - 
1.677) 
- 
1.000 
(False) 
32 
(5%) 
1.06(0.6244 
- 1.786) 
- 
 1.000 
(False) 
1.00 
1.04(0.59
06 -1.816) 
- 
1.000 
(False) 
Dominant CC 101 (16%) 122 
(19%) 
1.00 - 58(9%) 1.00 - 64 
(10%) 
1.00 - 1.00 - 
CT + TT 179 (28%) 165 
(26%) 
1.09 
(0.7832 - 
1.508) 
 
1.000 
(False) 
129 
(20%) 
1.25 (0.8459 - 
1.862) 
 
1.000 
(False) 
106 
(17%) 
1.07(0.7210 
- 1.588) 
 
1.000 
(False) 
1.34(0.86
61 - 
2.082) 
 
0.748 
(False)  
 Recessive CC + CT 228 (36%) 287 
(45%) 
1.07 
(0.7177 - 
1.594) 
 
1.000 
(False) 
149 
(23%) 
1.12 (0.7013 - 
1.783) 
 
1.000 
(False) 
138 
(22%) 
1.02 (0.6237 
- 1.657) 
 
1.000 
(False) 
1.14(0.77
54 - 
1.673) 
 
1.000 
(False) 
  TT 52 (8%) 70 (11%) 1.00 - 38 
(6%) 
1.00 - 32 
(5%) 
1.00 - 1.00 - 
 Overdominant TT + CC 153 (24%) 192 
(30%) 
1.02 
(0.7419 -
1.393) 
 
1.000 
(False) 
96 
(15%) 
1.14 (0.7880 - 
1.655) 
 
1.000 
(False) 
96 
(15%) 
1.08(0.7336 
- 1.581) 
 
1.000 
(False) 
1.23(0.81
01 - 
1.867) 
 
1.000 
(False) 
  CT 127 (20%) 165 
(26%) 
1.00 - 91 
(14%) 
1.00 - 74 
(12%) 
1.00 - 1.00 - 
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Table 5: Genetic Association of Rs1014290 (GLUT 9) in Controls vs Pre-eclampsia (PE) groups 
 
*= denotes significance of p<0.05, **=p<0.01 and *** = p<0.001. The Bonferroni tests was used for multiple comparisons 
SNP GENETIC 
MODEL 
GENOTYPES CONTROL CONTROLS vs PE CONTROLS vs EOPE CONTROLS vs LOPE EOPE vs LOPE 
PE OR 
(95%CI) 
P- 
VALUE 
and 
Adjusted 
value  
EOPE OR 
(95% CI) 
P VALUE 
and 
Adjusted 
value 
LOPE OR 
(95%CI) 
P 
VALUE 
and 
Adjusted 
value 
OR 
(95%CI) 
P  
VALUE 
Rs1014290 Codominant CC  
CC vs TT 
20 (3%) 25 (4%) 1.00 
1.13(0.6
018 - 
2.109) 
- 
1.000 
(False) 
17 (3%) 1.00 
1.61 (0.7979 
- 3.235) 
- 
0.726 
(False) 
 8 (1%) 1.00 
1.45(0.614
1 -3.431) 
- 
1.000 
(False) 
1.00 
2.33(0.95
56 - 
5.692) 
- 
0.230 
(False) 
CT 
CC vs CT 
104 (16%) 159 
(25%) 
1.00 
1.22(0.6
462 - 
2.315) 
- 
1.000 
(False) 
88 
(14%) 
1.00 
1.01 (0.4957 
- 2.036) 
- 
1.000 
(False) 
71 
(11%) 
1.00 
1.71(0.712
3 - 4.090) 
- 
0.906 
(False) 
1.00 
1.71(0.69
93 - 
4.204) 
- 
0.939 
(False) 
TT 
CT vs TT 
155 (24%) 172 
(27%) 
1.00 
1.38 
(0.9914 - 
1.915) 
- 
0.224 
(False) 
82 
(13%) 
1.00 
1.60 (1.083 - 
2.363) 
- 
0.072 
(False) 
90 
(14%) 
1.00 
1.18(0.789
5 - 1.751) 
- 
1.000 
(False) 
1.00 
1.36(0.88
24 - 
2.097) 
- 
0.652 
(False) 
Dominant CC 20 (3%) 25 (4%) 1.00 - 17 (3%) 1.00 - 8 (1%) 1.00 - 1.00 - 
CT + TT 259 (41%) 331 
(52%) 
1.02 
(0.5554 - 
1.882) 
 
1.000 
(False) 
170 
(27%) 
1.29 (0.6593 
- 2.544) 
 
1.000 
(False) 
161 
(25%) 
1.55(0.668
6 - 3.612) 
 
1.000 
(False) 
2.01(0.84
50 - 
4.793) 
 
0.432 
(False) 
 Recessive CC + CT 124 (19%) 184 
(29%) 
1.34 
(0.9762 - 
1.832) 
 
0.280 
(False) 
105 
(16%) 
1.60 (1.102 - 
2.325) 
 
0.053 
(False) 
79 
(12%) 
1.09(0.747
7 -1.610) 
 
1.000 
(False) 
1.46(0.96
03 - 
2.216) 
 
0.305 
(False) 
  TT 155 (24%) 25 (4%) 1.00 - 82 
(13%) 
1.00 - 90 
(14%) 
1.00 - 1.00 - 
 Overdominant TT + CC 175 (27%) 197 
(31%) 
1.36 
(0.9859 - 
1.871) 
 
 
0.243 
(False) 
99 
(15%) 
1.50 (1.027 - 
2.179) 
 
0.142 
(False)  
98 
(15%) 
1.22(0.825
2 - 1.801) 
 
1.000 
(False) 
1.23(0.80
67 - 
1.866) 
 
1.000 
(False) 
  CT 104 (16%) 159 
(25%) 
1.00 - 88 
(14%) 
1.00 - 71 
(11%) 
1.00 - 1.00 - 
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ABSTRACT 
 Objective: To measure the concentration of plasma soluble angiotensin IV receptor (sAT-4), a 
component of the renin angiotensin system in healthy normotensive pregnancies and pre-eclampsia.  
Study Design: Stored maternal plasma samples obtained at time of diagnosis from pregnant women 
of African ancestry were stratified into normotensive and pre-eclampsia groups. Pre-eclampsia was 
subdivided into early onset, late onset, and into and severe pre-eclampsia. Plasma concentrations of 
sAT-4 were measured at 450nm using the ELISA technique (LNPEP KIT).  
Results: The systolic and diastolic blood pressure (BP) levels of the normotensive group were 
statistically lower compared to pre-eclampsia groups (p<0.05) and the mean gestational age in early 
onset pre-eclampsia was lower compared to late onset pre-eclampsia and the normotensive group 
(p<0.05). Plasma sAT-4 levels were significantly elevated (p<0.0001) in the normotensive group 
(median 1.95, range 1.89 – 2.02 ng/ml) compared to the pre-eclampsia group (median 1.55, range 
1.42 – 1.74 ng/ml), regardless of gestational age. Soluble AT-4 was decreased in relation to the 
severity of pre-eclampsia (p<0.001), the level in pre-eclampsia without severe features (median 1.57, 
range 1.42 – 1.74 ng/ml) was significantly higher than in pre-eclampsia with severe features (median 
1.51, range 1.42 - 1.55 ng/ml). There was no significant difference in the sAT-4 level between early 
onset pre-eclampsia (1.60±0.13 ng/ml) and late onset pre-eclampsia (1.65±0.29 ng/ml) groups 
(p=0.59).  
Conclusion: Plasma circulating levels of sAT-4 in women with severe features of pre-eclampsia had 
lower levels than normotensives and those with preeclampsia without severe features. 
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INTRODUCTION  
Preeclampsia (PE) is a pregnancy specific multisystemic disorder, characterized by widespread 
endothelial dysfunction with  clinical manifestations being end-organ dysfunction [1]. Pre-eclampsia 
causes substantial maternal and perinatal morbidity and mortality globally [2], and the exact cause is 
unknown [3]. More importantly, PE is a placental disorder therefore treatment requires the delivery 
of the fetus and placenta, however iatrogenic preterm delivery of the fetus and placenta is associated 
with obstetric and perinatal complications [2]. Despite several theories examining the pathogenesis 
of PE, molecular mechanisms underlying its precise development remains unclear [4]. 
 
During normal pregnancy, modification of cardiovascular function occurs, characterized by 
vasodilation that mediates increased blood flow to the uterus and kidneys [1]. The renin–angiotensin–
aldosterone system (RAAS) serves as a key regulator of electrolyte balance, fluid homeostasis, blood 
pressure and placentation [5].  
Normal placentation occurs in a low oxygen environment with hypoxia inducible factors (HIFs) 
modulating transcription genes involved in essential physiological processes that promote 
angiogenesis, cell proliferation, inflammation regulation of vascular tone and protection against 
oxidative stress [6]. The RAAS is involved in the early stages of placenta development thereby 
ensuring the development of a healthy pregnancy [7]. More specifically, angiotensin peptides viz., 
angiotensin II (Ang II) and the hexapeptide angiotensin IV (Ang IV) promote normal placentation [8-
10].  
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Angiotensin II and IV are highly expressed in early pregnancy and function by binding to angiotensin 
I (AT1R), angiotensin II (AT2R) and angiotensin IV (AT4R) receptors respectively [11]. The AT4 
receptor is a class II transmembrane protein often referred to as insulin regulated aminopeptidase 
(IRAP) or oxytocinase (OTase) [9, 10]. The activation of AT4R improves cell signal transmission, 
and it has both antioxidant and anti-inflammatory properties [12]. Off note, Ang IV elevates 
intracellular calcium to boost nitric oxide synthase (NOS) thereby modifying superoxide production 
[13]. A reduction in AT4R expression in PE placentae [8] and Ang II and Ang IV has been reported 
to result in deficient trophoblast invasion, non-physiological remodeling of myometrial spiral arteries, 
a decrease in nitric oxide, which is an effective tissue vasodilator  [4].  
The imbalance of RAAS components in circulation heralds the clinical signs of PE [1]. Despite the 
low expression of AT4R in the placentae of PE, circulating plasma levels of AT4R remains unknown 
in PE. Therefore, the aim of this study was to establish the concentration of plasma soluble Ang IV 
receptor (sAT-4) in PE vs healthy normotensive pregnancies stratified by gestational age and severity 
using the enzyme-linked immunosorbent assay (ELISA) technology.  
METHODS 
Study design 
This was a retrospective study consisting of a total of 250 stored maternal plasma samples obtained 
at the time of diagnosis from pregnant women of African ancestry. Written informed consent was 
obtained prior to sample collection from women recruited at a large regional hospital, South Africa. 
The study was approved by the Biomedical Research Ethics Committee at the University of KwaZulu-
Natal, South Africa (BCA338/17). Of the 250 women, 150 were normotensive pregnant (BP ≤120/80 
mmHg, with no obstetric complications) and 100 were pre-eclamptic (BP>≥140/90 mmHg). All 
participants were between the ages of 18-41 years. 
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Pre-eclampsia was defined as new onset hypertension (blood pressure of ≥140/90 mmHg taken on 
two occasions four hours apart and at least 1+ proteinuria measured by urinary dipstick) commencing 
at 20 weeks or more of gestation, with or without proteinuria and/or with evidence of liver disease, 
renal complications, thrombocytopenia, neurological dysfunctions [14]. The PE group was 
subdivided into early onset pre-eclampsia (EOPE), which refers to hypertension that occurs at ≤ 33 
weeks + 6 days of pregnancy and may result in the delivery of the fetus at < 34 weeks of gestation 
(n=50) and late onset pre-eclampsia (LOPE), which is hypertension that occurs at ≥ 34 weeks of 
pregnancy and may result in the delivery of the fetus at >34 weeks of gestation (n=50) [15]. Based 
on severity, the PE group was divided into the mild pre-eclampsia (n=69) and severe pre-eclampsia 
(n=31) groups. Pre-eclampsia without severe features (MPE) was defined as blood pressure of 
≥140/90 mmHg and ≤159/109 mmHg and proteinuria of ≥ 0.3 g but ≤ 2.0 g obtained from a 24 hour 
urine test or a 1+ to 2+ on a urine dipstick [16]. Pre-eclampsia with severe features (SPE) was 
identified as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg, with 
proteinuria ≥ 2.0 g in a 24- hour urine test or ≥3+ on a dipstick [16]. 
Patients with a previous history of hypertension, renal disease, liver disease or chronic hypertension 
and gestational hypertension were excluded from the study. Participants were matched according to 
maternal age and gestational age (weeks). 
Quantification of plasma circulating sAT-4  
The plasma sAT-4 level was determined using the Human LNPEP Assay Kit (Immuno-Biological 
Laboratories Co., Ltd Japan) according to the guidelines of the manufacturer. All the samples were 
analyzed in duplicate. The measurement range for this kit was 0.39 - 25ng/ml. Standard 
concentrations were plotted against absorbance to obtain a standard curve. The concentration of sAT-
4 in the different samples were obtained by extrapolating the absorbance of the test samples on the 
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standard curve. The measurement of sAT-4 concentration in the standards and test samples were done 
against a test sample blank at a wavelength of 450nm.   
Statistical analysis 
Results obtained in this study were analyzed using GraphPad Prism, V 5.03 (Graph-Pad Software 
Inc., California). Non-parametric method of data analysis was adopted as the sample size in the 
different experimental groups varied. The Mann-Whitney test was used to compare the results 
between the normotensive and the experimental groups. The Kruskal-Wallis test was also used to 
compare quantitative variables across the experimental groups. The patient demographic data are 
expressed as mean ± SD. In this study, a p-value < 0.05 was considered significant. 
 
RESULTS 
Table 1 represents the demographic data of all study groups. No significant differences were noted 
for maternal weight, maternal height, body mass index (BMI) and maternal age across all groups. 
However, systolic blood pressure, diastolic blood pressure and gestational age were significantly 
different across all three groups (p<0.05).  
sAT-4 Quantification 
The plasma circulating level of sAT-4 in the different experimental groups is graphically illustrated 
in There was a significantly higher level of circulating sAT-4 (p < 0.0001) in the normotensives 
(median 1.95, range 1.89 – 2.02 ng/ml) compared with the level in the PE (median 1.55, range 1.42 
– 1.74 ng/ml) (Figure 1).  Plasma sAT-4 level was significantly higher (p < 0.0001) in the 
normotensives (median 1.95, range 1.89 – 2.02 ng/ml) compared with the level in EOPE (median 
1.55, range 1.51 – 1.64 ng/ml) and LOPE (median 1.56, range 1.42 – 1.74 ng/ml) respectively. The 
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level of circulating sAT-4 in the early onset PE group did not statistically differ from that in the late 
onset PE group (p =0.59) (Figure 2). 
In figure 3, circulating level of sAT-4 in the normotensive group (median 1.95, range 1.89 – 2.02 
ng/ml) was significantly higher (p < 0.0001) compared with the level in PE without severe features 
(Mild PE;MPE) (median 1.57, range 1.42 – 1.74 ng/ml) and PE with severe features (severe PE;SPE) 
(median 1.51, range 1.42 - 1.55 ng/ml) respectively. It was also observed that the level of circulating 
sAT-4 in severe PE group was relatively lower compared to that in the mild PE group (p < 0.0005). 
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Discussion 
 Circulating sAT-4 levels were found to be lower in the PE compared to the healthy normotensive 
group (p<0.001). Furthermore, plasma sAT-4 levels were significantly lower in both the EOPE and 
LOPE subtypes compared to normotensive group (p<0.0001) and in PE without severe features and 
in PE with severe features, compared to healthy normotensive pregnancies (p<0.0001). The levels of 
sAT-4 were also observed to be significantly higher in PE with severe features, compared to PE 
without severe features respectively (p<0.0005). Despite clinical differences, sAT-4 levels were 
similar between EOPE and LOPE groups (p=0.59). Therefore, a variation was noted in the levels of 
sAT-4 in healthy normotensive groups compared to PE. Moreover, a significant variation was also 
observed with PE severity. 
Notably, circulating RAAS components are elevated in uncomplicated gestations [17]. It is plausible 
to hypothesize that an increase in AT4R expression in pregnancy serves as a regulatory mechanism 
to ensure Ang IV binding to AT4R rather than to AT1R [8]. This shift in AT4R and AT1R expression 
regulates the role of Ang IV in placental development during pregnancy [8]. Furthermore, a decreased 
expression of AT4R in early pregnancy negatively impacts trophoblast invasion a hallmark of PE 
development, and it may also cause a downregulation of Ang IV facilitated vasodilatation [8, 18, 19]. 
It has been reported that Ang IV receptors facilitate the activation of the nitric oxide synthase (NOS) 
isoform in the endothelial cells which helps in vasorelaxation [20]. This is due to Ang IV stimulating 
an increase in the release of intracellular calcium which in turn is essential for regulating NOS [21]. 
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Nonetheless, the results of the current study are corroborated by other reports that have also shown a 
significant decline in ATII and renin levels in PE [1, 5, 22]. Unlike AT1R and AT2R, AT4R is highly 
expressed throughout gestation [23, 24] highlighting its vital role in the maintenance of a successful 
pregnancy. Soluble AT4 is found on endothelial cells, smooth muscle cells, on the extravillous 
trophoblast and is responsible for trophoblast invasion [8]. A deficient extravillous trophoblast 
invasion leads to an absence of physiological conversion of myometrial spiral arteries in EOPE 
development [25]. In the current study, levels of sAT-4 were decreased compared to normal 
pregnancies. This probably explains the decrease noted in EOPE which is characterized by poor 
trophoblast invasion and abnormal remodeling of spiral arteries [25]. Nonetheless, oxidative stress 
emanating from poor placental perfusion contributes to the development of PE [26]. However, 
defective placentation is more pronounced in EOPE compared to LOPE [26, 27]. Early onset pre-
eclampsia is pathophysiologically different from LOPE and it is a more severe clinical form of the 
condition associated with renal diseases, characterized by an earlier gestational age, onset and 
delivery [28].  
This study is highlighted by the fact that it is the first, as far as we are aware, to compare the 
differences of plasma sAT-4 in healthy normotensives versus PE, as well as mild PE vs severe PE, 
we observed that 67.7% of the patients with severe features PE were of the EOPE type. Early onset 
pre-eclampsia is severely burdened with poor neonatal morbidity with prematurity, increased foetal 
growth restriction as well as small for gestational age babies[29]. Unlike EOPE, LOPE is 
characterised by a shorter duration of the ailment and it may be efficiently managed in settings with 
standard antenatal care services and also in cases where delivery of the baby is induced after the 37th 
week of gestation [29]. Markedly poor placental development in severe EOPE stimulates exaggerated 
inflammatory responses and causes a change in the intrauterine haemodynamic environment [30]. 
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These changes cause placental malperfusion which when coupled with increased “placental oxidative 
and ER stress” triggers EOPE development and its severity [29]. 
A key finding in our study is the significant decrease in sAT-4 based on severity of PE i.e. in PE with 
severe features compared to PE without severe features. These results are corroborated by other 
studies that report a correlation of significantly lower Ang II with an increase in the severity and 
clinical outcome in PE [1]. This difference of sAT-4 in PE with severe features compared to PE 
without severe features may be due to the difference in placental pathology of PE without severe 
features compare to PE with features. The placental pathology in this two sub groups of PE differs, 
in that PE with severe features is associated with more infarcts and syncytial knots compared to that 
in PE without severe features [31, 32]. This finding of a significant decrease in the level of sAT-4 in 
PE with severe features compared to PE without severe features throws more light on the evidence 
that these two conditions are distinctly different entities [33, 34]. 
Conclusion 
Plasma circulating level of sAT-4 decreased in PE. Women with severe features of PE have lower 
levels of s-AT4 than those without severe features and normotensives.  
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List of Figures 
Figure 1. Plasma sAT-4 level in Normotensives and PE (ng/ml). There was a significantly higher 
level of circulating sAT-4 (p < 0.0001) in the normotensives (median 1.95, range 1.89 – 2.02 ng/ml) 
compared with the level in the PE (median 1.55, range 1.42 – 1.74 ng/ml).  
 
Figure 2. Plasma sAT-4 level in Normotensives, early onset PE and late onset PE (ng/ml).  Plasma 
sAT-4 level was significantly higher (p < 0.0001) in the normotensives (median 1.95, range 1.89 – 
2.02 ng/ml) compared with the level in EOPE (median 1.55, range 1.51 – 1.64 ng/ml) and LOPE 
(median 1.56, range 1.42 – 1.74 ng/ml) respectively. The level of circulating sAT-4 in the early onset 
PE group did not statistically differ from that in the late onset PE group (p =0.59). 
 
Figure 3.  Plasma sAT-4 level in Normotensives, mild PE and severe PE (ng/ml). Shows the 
circulating level of sAT-4 in the normotensive group (median 1.95, range 1.89 – 2.02 ng/ml) was 
significantly higher (p < 0.0001) compared with the level in PE without severe features (Mild 
PE;MPE) (median 1.57, range 1.42 – 1.74 ng/ml) and PE with severe features (severe PE;SPE) 
(median 1.51, range 1.42 - 1.55 ng/ml) respectively. It was also observed that the level of circulating 
sAT-4 in severe PE group was relatively lower compared to that in the mild PE group (p < 0.0005). 
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Table 1: Patient Demographic Data 
 
Mean & 1SD Normotensive 
pregnant 
(n=100) 
 
PE (n=357)  
p-value 
2EOPE 
(n=50) 
3LOPE 
 (n=50) 
4MPE  
(n=31) 
5SPE  
(n=69) 
Age (years) 
Control vs 
EOPE 
Control vs 
LOPE 
EOPE vs LOPE 
Control vs MPE 
Control vs SPE 
MPE vs SPE 
28.60±5.90 28.19±7.35 
 
28.45±7.13 29.31±7.90 29.07±4.50  
p>0.05 
p>0.05 
p>0.05 
p>0.05 
p>0.05 
p>0.05 
BMI (Kg/M2) 
Control vs 
EOPE 
Control vs 
LOPE 
EOPE vs LOPE 
Control vs MPE 
Control vs SPE 
MPE vs SPE 
32.59±7.301 33.52±9.483 37.20±8.021 34.36±7.10 32.98±8.10  
p>0.05 
p<0.05 
p>0.05 
p>0.05 
p>0.05 
p>0.05 
Gestational Age 
(weeks) 
Control vs 
EOPE 
Control vs 
LOPE 
EOPE vs LOPE 
Control vs MPE 
Control vs SPE 
MPE vs SPE 
31.88±6.73 24.25±5.77 35.95±1.96 
 
34.46±3.72 31.89±4.60  
p<0.05 
p<0.05 
p<0.05 
p>0.05 
p>0.05 
p>0.05 
Systolic BP 
(mmHg) 
Control vs 
EOPE 
Control vs 
LOPE 
EOPE vs LOPE 
Control vs MPE 
Control vs SPE 
MPE vs SPE 
108.0±11.25 
 
161.10±4.13 149.51±6.13 146.8±5.55 165.5±4.57  
p<0.05 
p<0.05 
p>0.05 
p<0.05 
p<0.05 
p<0.05 
Diastolic BP 
(mmHg) 
Control vs 
EOPE 
65.52±9.38 
 
94.36±6.09 93.44±3.40 92.27±4.85 98.45±9.52  
p<0.05 
p<0.05 
p>0.05 
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Control vs 
LOPE 
EOPE vs LOPE 
Control vs MPE 
Control vs SPE 
MPE vs SPE  
p<0.05 
p<0.05 
p>0.05 
 
1SD-Standard Deviation, 2EOPE- Early onset Pre-eclampsia, 3LOPE-Late onset Pre-eclampsia, 
4MPEMild 
Pre-eclampsia, 5SPE- Severe Pre-eclampsia 
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Figure 1: Plasma sAT-4 level in Normotensives and PE (ng/ml). 
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Figure 2: Plasma sAT-4 level in Normotensives, early onset PE and late onset PE (ng/ml) 
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Figure 3:  Plasma sAT-4 level in Normotensives, mild PE and severe PE (ng/ml).
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Research Article: The Role of LNPEP and ANPEP Gene Polymorphisms in the 
Pathogenesis of Pre-eclampsia 
 
This research article focuses on the association of LNPEP and ANPEP gene polymorphisms in pre-
eclampsia: 
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Abstract  
The role of the renin angiotensin system in the pathogenesis of pre-eclampsia is well 
established. Pre-eclampsia is a leading cause of maternal and neonatal morbidity and mortality 
worldwide. Therefore, the aim of this study was to investigate the association of the angiotensin 
receptor 4 and aminopeptidase-N in the pathogenesis of pre-eclampsia. Stored blood samples 
of 637 South African women of African ancestry were utilized. The study population were 
divided into controls (n=280) and pre-eclampsia (n=357). Pre-eclampsia was sub-divided into 
early (n=187) and late (n=170) onset subtypes. DNA was extracted from whole blood and 
genotyped. Odds ratio and 95% confidence intervals were used to assess the association. The 
allele and genotype frequencies of the angiotensin receptor 4 and aminopeptidase-N showed 
no significant difference between the control versus the pre-eclampsia groups. Similarly, allele 
and genotype frequencies of the control group versus the subtypes of pre-eclampsia (early onset 
and late onset pre-eclampsia) showed no significant differences. The single nucleotide 
polymorphisms of angiotensin receptor 4 (rs18059) and aminopeptidase-N (rs6496603) are not 
associated with the pathogenesis of pre-eclampsia in women of African ancestry. 
Keywords: Pre-eclampsia, Angiotensin receptor 4, Aminopeptidase-N, Single nucleotide 
polymorphisms 
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Introduction 
Pre-eclampsia (PE) is a pregnancy specific disorder which presents clinically with hypertension 
and proteinuria [1]. It complicates 1-10% of pregnancies globally and is significantly 
associated with maternal and neonatal morbidity and mortality [2]. Although the aetiology of 
PE is poorly understood, it is widely accepted that it is characterised by an inadequate 
trophoblast invasion and lack of myometrial remodelling spiral arteries, with subsequent 
endothelial dysfunction [3].  
The involvement of the renin-angiotensin system (RAS) in the pathophysiology of PE has also 
been documented [4]. The chief function of RAS is to modulate blood pressure and electrolyte 
balance [4, 5]. The RAS is activated primarily by the enzyme renin released by juxtaglomerular 
cells of the kidney during low blood pressure and salt concentration [6]. The renin enzyme 
converts angiotensinogen released by the liver into angiotensin 1, which is catalysed by 
angiotensin-converting enzyme (ACE) to form the potent vasoconstrictor angiotensin II [7]. 
Angiotensin II (Ang II) binds to angiotensin 1 (ATR1) and angiotensin 2 (ATR2) receptors to 
perform its physiological function [8]. The key role of ATR1 is to activate vasoconstriction, 
regulate sympathetic activity, as well as in aldosterone release [8]. In contrast, AT2R is weakly 
expressed in the kidney, inhibits cell proliferation and stimulates cell death [9]. 
Angiotensin II may also be cleaved to form other Ang peptides such as the Ang (1-7), Ang III 
and Ang IV [10-12]. The enzyme facilitating the conversion of Ang III to Ang IV is 
aminopeptidase N (ANPEP) [13]. This protein is located on the brush border of proximal 
tubules [14-16]. It is involved in angiogenesis, inflammation, cell invasion and death hence is 
vital for pregnancy success [17]. 
Ang IV binds to AT1R and AT2R with low affinity but has a high affinity for the angiotensin 
receptor 4 (AT4R), also known as the leucyl-N-exopeptidase (LNPEP) [12]. AT4R is found on 
endothelial and smooth muscle cells where it binds Ang IV to mediate blood flow [18]. 
Furthermore, Ang IV is also found in the extravillous trophoblast (EVT) cells hence is involved 
in trophoblast invasion and spiral artery remodelling during the first trimester of pregnancy 
[19]. 
The AT4R is highly expressed in the heart, skeletal muscles kidneys, small intestine and the 
placenta [20]. Interestingly, the AT4R is up-regulated in early pregnancy placentae implicating 
its role in trophoblast migration [21]. High expression levels of the AT4R aid in Ang IV binding 
since it has a higher affinity for AT4R rather than AT1R [21]. The AT4R has been reported as 
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an antagonist of the ATIR. The binding of Ang IV to AT1R may lead to pregnancy 
complications. [22]. Elevated expression levels of ATIR in placentae of PE pregnancies 
compared to normotensive pregnancies have been reported [21, 23]. 
These alterations of RAS components have led to comprehensive investigations on their gene 
polymorphisms in hypertension, cardiovascular and renal diseases [24]. Siphai et al., (2009) 
demonstrated that gene polymorphism of the AT1R (A1166C) gene in Turkish patients are not 
associated with ischemic stroke. Likewise, Aung et al., (2017) demonstrated that 
polymorphisms of the AT1R (A1166C) and  AT2R (C3123A) SNPs were not associated with 
PE development in Black South African females [25].  
Existing data and information on the AT4R in pregnancy are very limited and poorly 
understood. In order to elucidate why the placental expression of AT4R are down-regulated in 
PE, this study aims to investigate the association of single nucleotide polymorphisms (SNPs) 
of AT4R viz., (LNPEP; rs18059) and ANPEP (rs6496603) in Black preeclamptic women of 
African ancestry. 
Materials and Methods 
Study population 
The samples utilized in this study were stored blood samples from pregnant women (n=637), 
obtained from a public sector hospital in Durban, South Africa. Informed consent for the 
storage and future studies was obtained from the Ethical Biomedical Committee at the 
University of KwaZulu-Natal (BCA338/17). The study population included normotensive 
pregnant (n=280) and PE (n=357) women. Pre-eclampsia was defined as high blood pressure 
(≥140/90 mmHg occurring during the second half of pregnancy (≥20 weeks of gestation) with 
proteinuria (≥300 mg in a 24-hour quantitative urine test/ +1 dipstick) or without proteinuria 
but with evidence of one or more of the conditions such as thrombocytopenia, raised liver 
enzymes, and abnormal renal function tests [26]. All demographic and clinical parameters were 
recorded at the time of hospital admission for PE patients during pre-natal visits. Controls were 
matched according to age and gestational age. 
DNA Isolation 
DNA was extracted from whole blood (500 µl) following the protocol from the Thermo 
Scientific GeneJet whole blood genomic DNA mini Kit (Thermo Scientific). Purified DNA 
samples were stored at -20°C for genotyping analysis. 
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Genotyping 
The SNPs (rs18059) of the LNPEP and (rs6496603) of ANPEP genes were genotyped from 
purified DNA samples using the TaqMan Universal PCR master mix (Applied Biosystems) 
following the manufacturer’s instructions (Life Technologies LTD, Warrington, UK). These 
primers (rs18059 and rs6496603) were amplified and allelic discrimination data were analysed 
using the Real-time Polymerase Chain Reaction (PCR) together with the StepOne v2.2.2 
Applied Biosystems software. 
Sample Size 
The sample size was calculated using the specified gene between cases and controls. A two-
fold difference in the level of gene was used based on a 95% probability level assuming 50% 
were controls.  The required sample size was 274 participants (137/group), with 80% power. 
However, a sample size of 637 participants was obtained respectively, sub-divided into the 
normotensive (280) group and the PE (357) group.  
Statistical Analysis 
Frequency and percentages were used to describe the presence of alleles and genotypes. Sub-
groups were compared using the Chi-square test or Fisher’s exact test as appropriate. The 
strength of association was reported as odds ratio (OR) and 95% confidence interval (CI) for 
categorical data and Wilcoxon rank sum tests for numerical data. A p-value of <0.05 was 
considered statistically significant. Demographical data were analysed using the one-way 
ANOVA test with the Graph pad prism 5 software (Graph pad Software, San Diego, CA, USA). 
Results 
The study population (n=637;100%) consisted of PE (n=357;56%) and normotensive pregnant 
(n=280;44%) participants. The PE group was divided into early onset (EOPE) (n=187;29%) 
and late onset (LOPE) (n=170;27%). 
Demographics and Analysis 
Table 1 validates demographic and clinical data amongst the three study groups. A significant 
difference was found for maternal age, gestational age, maternal weight, systolic, and diastolic 
blood pressure and proteinuria between normotensive pregnant vs EOPE and LOPE. 
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Genotyping 
An allelic and genotypic comparison of frequencies between PE and normotensive pregnant 
groups for SNPs LNPEP (rs18059) and ANPEP (rs6496603) are outlined in Table 2 and 3 
respectively. 
Allelic Association of LNPEP (rs18059) with Pre-eclampsia 
Pre-eclampsia (PE) vs Controls 
There was no significant association between the C (372 PE vs 317 controls) and T (332 PE vs 
241 controls) alleles (Table 2). 
Early onset (EOPE) and late onset (LOPE) Pre-eclampsia vs Controls 
Early onset PE vs controls showed no significant association for C and T alleles (C=189 EOPE 
vs 317 controls; T=177 EOPE vs 241 controls), and LOPE vs controls for both alleles were not 
significantly different (C=183 LOPE vs 317 controls; T=155 LOPE vs 241 controls). Similarly, 
the C and T alleles showed no significant difference between EOPE and LOPE (Table 2). 
Allelic Association of ANPEP (rs6496603) with Pre-eclampsia 
Pre-eclampsia (PE) vs Controls 
No significant difference was found for C (332 PE and 268 controls) and T (382 PE and 292 
controls) alleles in PE compared to the controls (Table 3). 
Early onset (EOPE) and late onset (LOPE) Pre-eclampsia vs Controls 
There was no significant difference between the C and T alleles in EOPE (C=180 EOPE and 
268 controls; T=194 EOPE and 292 controls) and LOPE (C=152 EOPE and 268 controls; 
T=188 EOPE and 292 controls) compared to the control group. No significance was noted 
between EOPE compared to LOPE (Table 3). 
Genotype Frequencies of LNPEP (rs18059) with Pre-eclampsia 
Pre-eclampsia (PE) vs Controls 
The genotype frequencies of rs18059 (CC, CT, and TT) showed no significant difference 
between PE (103, 166, and 83) versus the controls (95, 127 and 57); (Table 4). 
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Early onset and late onset Pre-eclampsia vs Controls 
A comparison of genotype frequencies for rs18059 (CC, CT, and TT) showed no significant 
association with EOPE (53,83 and 47) and LOPE (50,83 and 36) and controls (95,127 and 57); 
(Table 4). 
Genotype Frequencies of ANPEP (rs6496603) with Pre-eclampsia 
Pre-eclampsia (PE) vs Controls 
There was no significant difference between the genotypes of rs6496603 (CC, CT, and TT) in 
PE (72, 188 and 97) versus the controls (63,142 and 75); (Table 5). 
Early onset and late onset Pre-eclampsia vs Controls 
The genotype frequencies of rs6496603 (CC, CT, and TT) was not significantly different 
between EOPE (41, 98 and 48) and controls (63,142 and 75). Similarly, an absence of 
significant difference was noted between EOPE versus LOPE (31, 90 and 49) and between 
LOPE versus controls (Table 5). 
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Discussion 
The main findings of this study advocate that gene polymorphisms of the AT4R (LNPEP, 
rs18059) and ANPEP (rs6496603) genes are not associated with PE development. The results 
demonstrate no statistical difference in allele and genotype frequencies of LNPEP (rs18059) 
and ANPEP (rs6496603) between normotensive and PE pregnancies. Our results are similar to 
that of Aung et al., (2017) who found no significant associations of the gene polymorphisms 
of the RAS components; angiotensin-AGT (M235T), renin-REN (C-5312T), AT1R (A1166C), 
AT2R (C3123A) in PE compared to controls. Furthermore, Aung et al., (2017) found no 
association of these genes in PE subgroups (EOPE and LOPE) compared to controls [25]. 
Similarly, no significant differences in allele and genotype frequencies of the LNPEP (rs18059) 
and ANPEP (rs6496603) in normotensive pregnancies compared to EOPE and LOPE groups 
were noted respectively. Likewise, a comparison of alleles and genotype frequencies between 
EOPE and LOPE presented no significant difference. 
In contrast to the latter study, Akbar et al., (2009) observed frequencies of gene polymorphisms 
of AT1R and AT2R in different populations of women with PE compared to healthy 
normotensive pregnancies [27]. They found the AT2R (A1675G) polymorphism to be 
significantly higher in Afro-Caribbean women with PE compared to controls (p=0.004) [27]. 
Furthermore, Akbar et al., (2009) noted that AT1R (A1166C) was not significantly associated 
with PE in Afro-Caribbean, Caucasian and Asian women [27]. Additionally, Aung et al., 
(2017) and Roberts et al., (2004) reported similar results in a Zulu population group [28].   
Li et al., (2016) demonstrated that the AT1R (AGTR1; 275645) was significantly different 
between PE and the control group in a Chinese population (p=0.021) but found no significance 
between GH and the controls. However, angiotensinogen (AGT; rs3789678) was significantly 
associated with GH and not PE compared to the controls (p=0.0088) [29]. 
Also, Zangbar et al., (2018) studied different SNPs of AT1R (+1166A/C; rs5186) and AT2R 
(+1675A/G; rs5194) and noted no genotype and allele frequency differences between PE and 
controls. However, a combination of the genotypes of the two SNPs showed a statistical 
significance between PE and the control group. The AC/AG genotypes were lower in PE 
compared to controls, while the CC/AA genotypes were higher in PE compared to controls 
(p<0.01). These findings led to the conclusion that these polymorphisms are more likely to 
cause PE complications in pregnant women [30]. 
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The gene polymorphisms of the RAS were also investigated in patients with essential 
hypertension and the results obtained were analogous to results obtained from PE patients [31-
33]. In a Burkina Faso population with essential hypertension, gene polymorphisms of AGT 
and AT1R (AGT 235M/T, AT1R 1166A/C) were not associated with essential hypertension 
[32]. In contrast, Yang et al., (2015) found that the allele and genotype frequencies of ACE 
and AT1R in a Chinese Yi ethnic group were associated with essential hypertension (ACE 
G2350A, p=0.000, 0.002; AT1R A1166C: p=0.008, 0.011) [31]. 
In relation to AT4R, Pipkin et al., (2007) reported that the angiotensin peptide Ang IV acts via 
the AT4R on the placenta to stimulate angiogenesis, cell proliferation, inflammation, therefore 
AT4R contributes crucially to the development and preservation of a healthy pregnancy [34]. 
In addition, the Ang IV peptide physiologically moderates trophoblast invasion in the maternal 
endometrium, angiogenesis and endothelial dysfunction. In addition, Ang IV enhances nitric 
oxide activity, which is a potent vasodilator and contributes positively to maternal blood flow 
and endothelial dysfunction [21].  
Williams et al., (2010) noted a low expression of AT4R in the placenta of PE compared to 
healthy pregnancies [21]. Pre-eclampsia is characterized by poor trophoblast invasion, 
inflammation and endothelial dysfunction [35-38], changes which may be attributed to the 
decrease in the AT4R levels in PE. However, our results show that the rs18059 polymorphism 
of LNPEP is not associated with PE, therefore, other biochemical pathways may be associated 
with AT4R down-regulation.  
The binding of Ang IV to AT4R inhibits the action of the AT1R by boosting blood flow and 
inhibiting sodium reabsorption by the kidneys, thus regulating blood pressure [10]. Moreover, 
Mistry et al., (2013) noted that AT1R is highly expressed in pre-eclamptic placentas [23]. Also 
the binding of Ang II to AT1R promotes vasoconstriction, peripheral vascular resistance, 
defective angiogenesis, cell proliferation and vascular permeabilityall factors that are 
dysregulated in PE [39]. Since AT1R is also a binding site for Ang IV , it may also contribute 
to the pathology of PE when highly expressed [21]. Many previous studies corroborate our 
findings and report no association of gene polymorphisms of the RAS with PE development 
[11, 25, 28, 29].  
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Strengths, Limitations and Future Recommendations 
The study was conducted in a homogenous population of African ancestry in which the 
prevalence of PE is high. The limitation of this study was that only one single nucleotide 
polymorphism (SNP) was tested in both the LNPEP and the ANPEP gene. Other 
polymorphisms of the same genes need to be investigated in PE to confirm that the genes of 
the RAS components are not associated with PE. 
Conclusion 
Despite reports on low AT4 expression levels in placentae of women with PE, the role of RAS 
genes in PE remains unclear. Several investigations on the gene polymorphisms of RAS 
components have revealed an absence of association with pre-eclampsia development. 
Similarly, our results show that the gene polymorphisms of the AT4 receptor (LNPEP; 
rs18059) and aminopeptidase-N (ANPEP; rs6496603) are not associated with PE in women of 
African ancestry. We recommend further investigations to examine additional RAS genes in 
the pathogenesis of PE. 
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TABLE 1: Patient Demographics and Clinical Data 
Mean & 1SD Normotensive 
pregnant 
(n=280) 
 
PE 
(n=357) 
 
p-value 
2EOPE (n=187) 3LOPE (n=170) 
Maternal Age (years) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
26.78±6.5 29.76±6.5   27.29±6.8  
<0.0001*** 
0.9701ns 
<0.0001*** 
Systolic BP (mmHg) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
109.8±12.3 158.9±13.7 151.4±12.1  
<0.0001*** 
<0.0001*** 
0.0026** 
Diastolic BP (mmHg) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
 
 67.65±8.4 102.0±9.3 98.23±6.6  
<0.0001*** 
<0.0001*** 
0.0300* 
Gestational Age 
(weeks) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
 
38.24±1.7 28.51±4.2 37.06±1.9  
 
<0.0001*** 
<0.0001*** 
<0.0001*** 
Maternal Weight (Kg) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
 
72.79±16.8 81.96±18.5 73.48±18.2  
0.0120* 
0.2253ns 
0.3585ns 
Proteinuria (mg) 
Control vs EOPE 
Control vs LOPE 
EOPE vs LOPE 
0.00±0.06 1.51±0.74 1.44±0.69  
<0.0001*** 
<0.0001*** 
0.4970ns 
 
A p-value of <0.05 was considered statistically significant, ***= highly significant with a p-
value of <0.001, **= p<0.01, ns= not significant. 
1SD= standard deviation; 2EOPE =early onset preeclampsia; 3LOPE =late onset preeclampsia 
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TABLE 2: Allele Frequencies of LNPEP (rs18059) in Pre-eclampsia vs Controls 
 
  
FREQUENCIES 
CC, CT, TT (rs18059) 
ALLELE 
Rs18059-LNPEP 
OR (95%CI) 
p-value 
Controls (n=280;44%) PE vs CONTROL  
CC=95 (14.9%)  C vs T 1.174 (0.9387 - 1.468) 
p=0.1596 
CT=127 (19.9%) CC vs CT/TT 1.248 (0.8904 - 1.750) 
p=0.1979 
TT=57 (8.9%) CC/CT vs TT 1.202 (0.8208 - 1.759) 
p=0.3443 
PE (n=357;56%) EOPE vs CONTROLS  
CC=103 (16.2%) C vs T 1.232 (0.9453 - 1.605) 
p=0.1225 
CT=166 (26.1%) CC vs CT/TT 1.266 (0.8453 - 1.897) 
p=0.2516 
TT=83 (13.0%) CC/CT vs TT 1.346 (0.8657 - 2.093) 
p=0.1861 
EOPE (n=187;29%) EOPE vs LOPE  
CC=53 (8.3%) C vs T 1.106 (0.8221 - 1.487) 
p=0.5063 
CT=83 (13.0%) CC vs CT/TT 1.031 (0.6509 – 1.632) 
p=0.8977 
TT=47 (7.4%) CC/CT vs TT 1.277 (0.7778 - 2.096) 
p=0.3333 
LOPE (n=170;27%) LOPE vs CONTROLS  
CC=50 (7.8%) C vs T 1.114 (0.8490 - 1.462) 
p=0.4357 
CT=83 (13.0%) CC vs CT/TT 1.229 (0.8131 - 1.857) 
p=0.3276 
TT=36 (5.7%) CC/CT vs TT 1.054 (0.6592 - 1.686) 
p=0.8255 
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Table 3: Frequency Alleles of ANPEP (rs6496603) in Pre-eclampsia groups vs Controls 
 
  
FREQUENCIES 
CC, CT, TT  
(rs6496609) 
ALLELE 
Rs6496603-ANPEP 
OR (95%CI) 
p-value 
Controls (n=280;44%) PE vs CONTROL  
CC=63 (9.9%) C vs T 1.056 (0.8461 - 1.318) 
p=0.6297 
CT=142 (22.3%) CC vs CT/TT 1.149 (0.7847 - 1.683) 
p=0.4747 
TT=75 (11.8%) CC/CT vs TT 1.020 (0.7167 - 1.451) 
p=0.9135 
PE (n=357;56%) EOPE vs CONTROLS  
CC=72 (11.3%) C vs T 1.011 (0.7779 - 1.314) 
p=0.9352 
CT=188 (29.5%) CC vs CT/TT 1.034 (0.6619 - 1.615) 
p=0.8837 
TT= 97 (15.2%) CC/CT vs TT 1.059 (0.6950 - 1.615) 
p=0.7882 
EOPE (n=187;29%) EOPE vs LOPE  
CC=41 (6.4%) C vs T 1.148 (0.8546 - 1.541) 
p=0.3598 
CT=98 (15.4%) CC vs CT/TT 1.259 (0.7477 - 2.121) 
p=0.3855 
TT=48 (7.5%) CC/CT vs TT 1.173 (0.7353 - 1.870) 
p=0.5033 
LOPE (n=170;27%) LOPE vs CONTROLS  
CC=31 (4.9%) C vs T 1.135 (0.8660 - 1.488) 
p=0.3582 
CT=90 (14.1%) CC vs CT/TT 1.302 (0.8056 - 2.104) 
p=0.2806 
TT=49 (7.7%) CC/CT vs TT 1.107 (0.7240 - 1.692) 
p=0.6390 
90 
 
TABLE 4: Genotype Frequencies of LNPEP (rs18059) in Pre-eclampsia groups vs Controls 
FREQUENCIES 
CC, CT, TT (rs18059) 
GENOTYPE 
Rs18059-LNPEP 
OR (95%CI) 
p-value 
Controls (n=280;44%) PE vs CONTROL  
CC=95 (14.9%)  CC vs TT 1.343 (0.8670 - 2.080) 
p=0.1860 
CT=127 (19.9%) CC vs CT 1,206(0.8392 - 1.732) 
p=1.206 
TT=57 (8.9%) CT vs TT 1.114 (0.7402 - 1.677) 
p=0,6045 
PE (n=357;56%) EOPE vs CONTROLS  
CC=103 (16.2%) CC vs TT 1.478 (0.8857 - 2.466) 
p=0.1340 
CT=166 (26.1%) CC vs CT 1.171 (0.7580 - 1.810) 
p=0,4760 
TT=83 (13.0%) CT vs TT 1.262 (0.7845 - 2.029) 
p=0.3372 
EOPE (n=187;29%) EOPE vs LOPE  
CC=53 (8.3%) CC vs TT 1.232 (0.6887 - 2.203) 
p=0.4820 
CT=83 (13.0%) CC vs CT 1.060 (0.6481 - 1.734) 
p=0.8164 
TT=47 (7.4%) CT vs TT 1.306 (0.7683 - 2.219) 
p=0.3237 
LOPE (n=170;27%) LOPE vs CONTROLS  
CC=50 (7.8%) CC vs TT 1.200 (0.6994 - 2.059) 
p=0.5078 
CT=83 (13.0%) CC vs CT 1.242 (0.7995 - 1.929) 
p=0.3348 
TT=36 (5.7%) CT vs TT 1.035 (0.6272 - 1.707) 
p=0.8935 
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Table 5: Genotype Frequencies of ANPEP (rs6496603) in Pre-eclampsia groups vs Controls 
FREQUENCIES 
CC, CT, TT  
(rs6496609) 
GENOTYPE 
Rs6496603-ANPEP 
OR (95%CI) 
p-value 
Controls n=280;44%) PE vs CONTROL  
CC=63 (9.9%) CC vs TT 1.132 (0.7194 - 1.780) 
p=0.5924 
CT=142 (22.3%) CC vs CT 1.158 (0.7747 - 1.732) 
p=0.4734 
TT=75 (11.8%) CT vs TT 1.024 (0.7057 - 1.485) 
p=0.9019 
PE (n=357;56%) EOPE vs CONTROLS  
CC=72 (11.3%) CC vs TT 1.017 (0.5956 - 1.736) 
p=0.9511 
CT=188 (29.5%) CC vs CT 1.060 (0.6627 - 1.697) 
p=0.8066 
TT= (15.2%) CT vs TT 1.078 (0.6914 - 1.682) 
p=0.7394 
EOPE (n=187;29%) EOPE vs LOPE  
CC=41 (6.4%) CC vs TT 1.350 (0.7311 - 2.493) 
p=0.3368 
CT=98 (15.4%) CC vs CT 1.215 (0.7026 -2.100) 
p=0.4859 
TT=48 (7.5%) CT vs TT 1.112 (0.6808 - 1.815) 
p=0.6723 
LOPE (n=170;27%) LOPE vs CONTROLS  
CC=31 (4.9%) CC vs TT  1.328 (0.7577 - 2.327) 
p= 0.3213 
CT=90 (14.1%) CC vs CT 1.288 (0.7776 - 2.134) 
p=0.3249 
TT=49 (7.7%) CT vs TT 1.031 (0.6595 - 1.611) 
p= 0.8940 
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6.1 SYNTHESIS, CONCLUSIONS AND FUTURE RESEARCH  
 
To-date, the etiology of PE remains a perplexity worldwide. Pre-eclampsia is a multisystem disorder, 
that requires ongoing research to elucidate its underlying etiology (Gathiram and Moodley, 2016). 
Globally, 2-10% of pregnancies are affected by PE at ≥20 weeks of gestation, resulting in maternal 
and fetal morbidity and mortality (Kamath, 2006). Although the etiology is an enigma, the clinical 
signs and symptoms are well established. These include hypertension (≥140 mmHg systolic BP and 
≥ 90 mmHg diastolic BP), proteinuria (>0.3 mg) or without proteinuria with one of the following 
conditions; thrombocytopenia, liver or renal dysfunctions, neurological disorders and fetal growth 
restriction (Brown et al., 2018). The exact cause of PE is unknown; however, the pathophysiology 
involves poor trophoblast invasion into the spiral arteries, resulting in irregular spiral artery 
remodeling, which triggers placental hypoxia and ischemia. These factors activate maternal systemic 
inflammation, endothelial dysfunction, hypertension, proteinuria and hyperuricemia (Redman and 
Sargent, 2005). 
In South Africa, hypertension in pregnancy accounts for above 14% of all maternal deaths and is a 
direct contribution to maternal mortality (Saving Mothers 2014-2016, 2017). Moreover, the condition 
is affected by HIV infection in pregnancy, in fact 30% of parturients in SA are HIV infected (Kalumba 
et al., 2013).  To-date, the etiology of PE remains a perplexity worldwide. Pre-eclampsia is associated 
with injury to the kidney and it is well documented that uric acid is elevated in PE (Nair and Savita 
2017).  
The role of hyperuricemia in PE is poorly described, therefore this thesis investigated the role of uric 
acid in PE as a causative factor or a symptom of the disease. The review indicated discrepancies 
amongst other studies (Bainbridge and Roberts, 2008;Chen et al., 2016; Kondareddy and Prathap, 
2016; Priya et al., 2016; Staff and Redman, 2016). Bainbridge et al., (2008) identified hyperuricemia 
as a pathogenic factor of PE since women with hyperuricemia at 10 weeks of gestation developed PE 
later in pregnancy. In contrast, Kondareddy and Prathap, (2016) suggested that hyperuricemia 
occurred after the clinical signs of PE in some patients, and stated that high levels cannot be a 
pathogenic factor, a predictor or a biomarker of the disease (Kondareddy and Prathap, 2016). In 
addition, William and Galerneau, (2002) suggested that serum uric acid levels were not significantly 
elevated in PE compared to normal pregnancies (Williams and Galerneau, 2002).  
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The above debates on the role of uric acid in PE led to the first objective of the current study, which 
was to investigate the association of gene polymorphisms of uric acid levels (URAT1; rs505802, 
GLUT 9; rs1014290; PDZK1 CD160; rs12129861) in PE. Early in normal gestation, uric acid levels 
rise, with a gradual decline as the pregnancy progresses reaching an equilibrium to equate that of non-
pregnant women at term (Parrish et al., 2010). Moreover, in pre-eclamptic pregnancies, this elevation 
results in hyperuricemia (Mustaphi et al., 1996).  
 
Hyperuricemia of gout is known to be associated with polymorphisms of various uric acid related 
genes viz., rs1014290 (SLC2AL; GLUT9): rs505802 (SCL22A12; URAT1): rs12129861 (PDZK1; 
CD160)] (Zhang et al., 2013; Sun et al., 2014; Zhang et al., 2016). We report that of the four SNPs 
selected in our study, rs2231142 (ABCG2) had a frequency of <1% in women of African ancestry. 
We also show that SNPs rs505802 (URAT 1) and rs1014290 (GLUT 9) rather than rs12129861 
(PDZK1 CD160) were significantly associated with PE.  
 
The URAT 1 transporter gene is located within the proximal tubules where uric acid reabsorption 
occurs. We found a significantly higher prevalence of the SNP (rs505802) in PE (37%) compared to 
healthy pregnancies (31%) and EOPE (31%). These results are tabulated in chapter 3 (table 2-5) and 
include; the frequencies of the alleles and genotypes of all the urate transporter genes as well as their 
association, in PE vs normotensives, which is reported as odds ratio at 95% confidence interval and 
a p value of <0.05 was considered significant. Our findings are supported by an association of the 
URAT 1 gene with an inflammatory response in non-pregnant women with metabolic syndrome, 
hypertension and obesity (Shafiu et al., 2012). Similar clinical manifestations have been reported in 
LOPE, (Madazli et al., 2014) which, according to our findings is influenced by the URAT 1 SNP 
(rs505802). Moreover, the association of rs505802 with hyperuricemia has been previously 
demonstrated (Cho et al., 2015). Using a Chinese cohort with cardiovascular disease, Kolz et al., 
(2009) reported that patients with hyperuricemia also presented with exaggerated blood pressure, 
diabetes, insulin resistance and obesity (Kolz et al., 2009), all medical conditions associated with PE 
development (English et al., 2015).  
 
In the current study, the heterozygous genotype CT of rs505802 demonstrated a higher frequency in 
PE compared to healthy pregnancies. Therefore, individuals with the CT genotype were twofold more 
likely to be preeclamptic. These findings are analogous to various other studies that have suggested 
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that PE is of heterozygous origin with variation by ethnicity (Valenzuela et al., 2012; Rudic et al., 
2018).  
 
In contrast the PDZK1 CD160 SNP (rs12129681) in our study showed no significant association with 
PE despite its association with hyperuricemia in gout (Kolz et al., 2009; Wright et al., 2010; Reginato 
et al., 2012;Sun et al., 2014; Roman et al., 2016).  
 
In our study GLUT 9 (rs1014290) was significantly associated with EOPE compared to normotensive 
pregnant women. The CT genotype was more prevalent within the EOPE group (47%) compared to 
controls (37%), confirming that women of African ancestry with the CT genotype have a 1.5 times 
risk of PE development. The GLUT 9 gene is a uric acid transporter within kidney and liver cells 
(Mobasheri et al., 2002). Our findings are in accordance with studies that show an association of 
rs1014290 with hyperuricemia in gout (Li et al., 2007; Stark et al., 2008; Preitner et al., 2009; Urano 
et al., 2010; Parsa et al., 2012; Testa et al., 2014; Meng et al., 2015; Ruiz et al., 2018). Moreover, the 
association between hyperuricemia and hypertension has been demonstrated across both sexes (Wang 
et al., 2014). Additionally, Parsa et al., (2012) reported that the consequence of a mutation of the 
GLUT 9 gene was hypertension development (Parsa et al., 2012). 
 
In our study, the rs1014290 SNP was associated with EOPE, a sub-type of PE characterized by 
defective placentation with/without renal injury, revealed by proteinuria. It is widely accepted that 
uric acid provokes endothelial dysfunction, hypertension, vascular resistance and renal disease 
(Sultana et al., 2013). Early onset pre-eclampsia  is associated with abnormal placentation and a lack 
of myometrial spiral artery remodeling (Gomathy et al., 2018). Furthermore, EOPE presents with an 
aggressive hematological, arterial, renal, hepatic adverse maternal and fetal outcome in comparison 
to LOPE.  An inactivation of the gene coding for GLUT 9 in hepatic cells of mice results in 
hyperuricemia, therefore it is plausible that a consequence of liver pathology in EOPE may be due to 
GLUT 9 inactivation (Gomathy et al., 2018). 
 
The second objective of our study was to assess the plasma concentration of the receptor (sAT-4), in 
pre-eclampsia. Soluble AT4 receptor is a vital component of RAS (Williams et al., 2010). The 
activation of AT4 receptor (AT4R) improves cell signal transmission, and it has both anti-oxidant 
and anti-inflammatory properties (Wright et al., 2015). Soluble AT4R is a binding ligand for 
angiotensin IV which mediates blood flow and normal placentation by its involvement in extravillous 
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trophoblast invasion (Williams et al., 2010). Importantly, Ang IV elevates intracellular calcium to 
boost nitric oxide synthase (NOS), which is a crucial vasodilator (Patel et al., 1998). A reduction in 
Ang IV results in poor trophoblast invasion, poor placentation, vasoconstriction and subsequently PE 
development.  
 
In the present study, a significant decrease in sAT-4R was noted in PE, EOPE, LOPE, mild PE (MPE) 
and severe PE (SPE) compared to normotensive pregnant women of African ethnicity. Moreover, 
SPE levels were also significantly different to MPE. Our findings are in keeping with other studies 
that observed a significant decrease in ATII and renin levels in PE (Kurlak et al., 2019a). Furthermore, 
a significant down-regulation in sAT-4 was reported in PE compared to normotensive placentae 
(Williams et al., 2010). The AT4R is highly expressed throughout gestation in normal pregnancies, 
portraying its necessity to maintain a successful pregnancy. A decline in AT4 expression leads to 
poor extravillous trophoblast invasion resulting in an absence of the physiological conversion of 
myometrial spiral arteries in EOPE development (Reister et al., 2006). Furthermore, oxidative stress 
emanating from poor placental perfusion contributes to the development of PE (Redman et al., 2014). 
 
Another primary finding in our study was the significant decrease of sAT-4 aligned with the severity 
of PE. This finding is corroborated with other studies that observed a significant decrease of Ang II 
(Leaños-Miranda et al., 2018). Notably in our study, 67.7% of SPE were EOPE women. Early onset 
pre-eclampsia  correlates with neonatal morbidity, premature births, fetal growth restrictions and 
small for gestational age babies (Staff and Redman, 2018), complications emanating from poor 
placentation and a hypoxic microenvironment that is detrimental to the fetus (Herzog et al., 2017). 
 
The last objective of our study was to compare variant gene polymorphisms of AT4 (rs18059) and 
ANPEP (rs6496603) with pre-eclampsia development. Since the AT4 receptor levels are altered in 
PE pregnancies, it is vital that one evaluates the underlying cause for this dysregulation. The RAS is 
a significant contributor to blood pressure regulation and salt retention and a dysregulation of any 
component may compromise maternal and fetal health (Shah, 2005). In pregnancy, the different 
components of RAS function synergistically to maintain a homeostatic environment for fetal 
development (Chung et al., 1998). These components include Ang II which binds to AT1R and AT2R 
for activation as well as Ang III and Ang IV. The conversion of Ang III to IV is mediated by ANPEP, 
which plays a fundamental role in angiogenesis, cell invasion, cell death and inflammation, 
designating its importance in a healthy pregnancy (Poumarat et al., 2002). Ang IV on the other hand 
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binds to the AT4 receptor (LNPEP) for functionality. It increases blood flow, mediates proper 
extravillous trophoblast invasion and activates nitric oxide for vasodilation of endothelial cells 
(Williams et al., 2010). A down-regulation of either Ang IV or its receptor may be detrimental to 
maternal and fetal health.  
 
Our study demonstrates no significant association of LNPEP (rs18059) and ANPEP (rs6496603) 
SNPs with PE development in a homogenous Black African population. These findings are 
corroborated by Aung et al., 2017 who reported no significance in the frequencies of the ATIR SNPs 
(A1166C), AT2R (C3123A), angiotensin-AGT (M235T), renin-REN (C-5312T) in PE compared to 
normotensive controls in the same population (Aung et al., 2017). In contrast, Akbar et al., (2009) 
observed a significant increase in frequencies of AT2R (A1675G) in Caribbean women with PE 
compared to healthy pregnancies. However, analogous to Aung et al., 2017, Akbar et al., 2009 noted 
that ATIR (A1166C) was similar amongst Afro-Caribbean, Caucasian and Asian women with PE 
compared to those with normotensive pregnancies (Akbar et al., 2009).  
 
Our study supports the evidence that PE is of heterozygous origin. Also, we are the first to report on 
the association of uric acid polymorphisms in PE and our findings depict that uric acid polymorphisms 
are associated with the pathogenesis of PE. Moreover, the RAS system is dysregulated in PE and this 
study shows that sAT-4 levels in circulation are lower in PE compared to normotensive pregnant 
women. However, gene polymorphisms of the RAS show no significant association with PE. 
 
6.2 CONCLUSIONS  
In conclusion, our review has shown that uric acid levels may be elevated in the first trimester of 
pregnancy. This elevation may emanate from the glomerular endotheliosis and contribute to the 
deficient trophoblast invasion and lack physiological spiral artery remodeling. This study 
demonstrates for the first time, polymorphisms of uric acid genes (URAT 1; rs505802 and GLUT 9; 
rs1014290). These two genes were significantly associated with the pathogenesis of PE in women of 
African ancestry hence may be used to genetically test for the risk of PE development. The increased 
retention of uric acid enhances sympathetic activity thereby decreasing the angiotensin system action 
and exacerbating the existing hypertension in PE. Moreover, we show that the AT4 receptor gene 
(LNPEP) and ANPEP are not significantly associated with PE development in a homogenous Black 
African population. However, sAT-4 plasma levels in PE are lower than normal pregnancies. This 
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decline in sAT-4 levels may negatively impact trophoblast invasion and may also cause a down 
regulation of angiotensin IV facilitated vasodilatation. Nonetheless, this finding of a downregulation 
of s-AT4 pre-eclampsia with severe features compared with PE with mild features reflects that these 
two conditions are distinctly different entities. 
 
6.3 FUTURE RESEARCH 
Further investigations are required to confirm the association of uric acid with the pathogenesis of PE 
in an independent cohort. Furthermore, the involvement of the RAS with PE is poorly understood 
since concentrations of the RAS components are dysregulated, but their SNPs show no significant 
association with the disease. There is a need for further research in this regard for the improvement 
in the management of PE for healthier pregnancy outcomes. It is also important to note that is it 
challenging to perform studies on genes, therefore case-control studies should be matched correctly 
in genetic studies. Since it is difficult to implicate a single SNP with a disease, for future studies, a 
mendalian randomization test would be useful to test the cause-effect of genes in pre-eclampsia. 
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